



**HAL**  
open science

## Regulation of the macrolide resistance ABC-F translation factor MsrD

Corentin Fostier, Farès Ousalem, Elodie Leroy, Saravuth Ngo, Heddy Soufari,  
C. Axel Innis, Yaser Hashem, Grégory Bo l

► **To cite this version:**

Corentin Fostier, Farès Ousalem, Elodie Leroy, Saravuth Ngo, Heddy Soufari, et al.. Regulation of the macrolide resistance ABC-F translation factor MsrD. 2022. hal-03795511

**HAL Id: hal-03795511**

**<https://hal.science/hal-03795511v1>**

Preprint submitted on 4 Oct 2022

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20

**Regulation of the macrolide resistance ABC-F translation factor MsrD**

**Corentin R. Fostier<sup>1</sup>, Farès Ousalem<sup>1</sup>, Elodie C. Leroy<sup>2</sup>, Saravuth Ngo<sup>1</sup>,  
Heddy Soufari<sup>2,3</sup>, C. Axel Innis<sup>2</sup>, Yaser Hashem<sup>2,\*</sup>, Grégory Boël<sup>1,4,\*</sup>**

<sup>1</sup>Expression Génétique Microbienne, CNRS, Université Paris Cité, Institut de Biologie Physico-Chimique, 75005 Paris, France

<sup>2</sup>INSERM U1212 (ARNA), Institut Européen de Chimie et Biologie, Université de Bordeaux, 33607 Pessac, France

<sup>3</sup>Current address: NovAliX, Boulevard Sébastien Brant, Bioparc, 67405 Illkirch Cedex, France

<sup>4</sup>Lead contact

\*Correspondence:

Grégory Boël, Institut de Biologie Physico-Chimique, 13 rue Pierre et Marie Curie, 75005 Paris, France, tel. : +33 (0) 1 58 41 51 21; e-mail: [boel@ibpc.fr](mailto:boel@ibpc.fr)

Yaser Hashem, Institut Européen de Chimie et Biologie, Université de Bordeaux, 33607 Pessac, France, tel. : +33 (0) 5 40 00 88 22; e-mail: [yaser.hashem@inserm.fr](mailto:yaser.hashem@inserm.fr)

21 **SUMMARY**

22 Antibiotic resistance ABC-Fs (ARE ABC-Fs) are translation factors currently proliferating  
23 among human pathogens that provide resistance against clinically important ribosome-  
24 targeting antibiotics. Here, we combine genetic and structural approaches to determine the  
25 regulation of *streptococcal* ARE ABC-F gene *msrD* in response to macrolide exposure and  
26 also demonstrate that MsrD twin-ATPase sites work asymmetrically to mediate the dynamic of  
27 MsrD interaction with the ribosome. We show that cladinose-containing macrolides lead to  
28 insertion of MsrDL leader peptide into an undocumented conserved crevice of the ribosomal  
29 exit tunnel concomitantly with 23S rRNA rearrangements that prevent peptide bond formation  
30 and preclude accommodation of release factors. The stalled ribosome obstructs formation of  
31 a Rho-independent terminator which prevents *msrD* transcriptional attenuation. This stalled  
32 ribosome is rescued by MsrD, but not by MsrD mutants which do not provide antibiotic  
33 resistance, showing evidence of equivalence between MsrD function in antibiotic resistance  
34 and its action on this complex.

35

36 **KEYWORDS**

37 Ribosome, protein synthesis, antibiotic resistance, ARE ABC-F protein family, leader peptide,  
38 cryo-EM.

## 39 INTRODUCTION

40 ABC-F ATPases belonging to the ATP-Binding Cassette (ABC) superfamily are  
41 translation factors and some of them, termed antibiotic resistance ABC-Fs (ARE ABC-Fs),  
42 confer resistance to clinically important antibiotics that bind to the ribosomal peptidyl  
43 transferase center (PTC) and/or the nascent peptide exit tunnel (NPET)<sup>1-7</sup>. ABC-F proteins are  
44 composed of two ABC domains (or Nucleotide Binding Domains, NBDs) joined by a linker  
45 region called P-site tRNA-interaction motif (PtIM)<sup>8,9</sup>, also termed antibiotic resistance  
46 determinant (ARD) for ARE ABC-Fs<sup>1-3</sup>. The two ABC domains dimerize after binding of two  
47 ATP molecules and in this conformation the factor can bind the ribosomal E-site<sup>9</sup>, where the  
48 PtIM adopts an  $\alpha$ -helical hairpin conformation that interacts directly with the peptidyl-tRNA and  
49 extends toward the PTC/NPET. Three antibiotic resistance phenotypes are associated with  
50 ARE ABC-Fs: (i) MKS<sub>B</sub> (Macrolides, Ketolides, Streptogramins group B); (ii) PLS<sub>A</sub>  
51 (Pleuromutilins, Lincosamides, Streptogramins group A); (iii) PhO (Phenicols,  
52 Oxazolidinones)<sup>10,11</sup>. However, despite structural investigations<sup>1-3,5,7</sup>, the exact molecular  
53 mechanism of action of ARE ABC-Fs remains unclear.

54 Over the last forty years, biochemical and structural investigations demonstrated the  
55 ability of elongating nascent chains (NC) into the ribosomal tunnel to interact with metabolites  
56 or antibiotics, thus adapting protein synthesis to environmental cues<sup>12-16</sup>. In human pathogens,  
57 antibiotic-dependent formation of stalled ribosome complexes (SRCs) on regulatory ORFs,  
58 named leader peptides, can subsequently allow regulation of downstream resistance genes in  
59 response to antibiotic exposure<sup>17-20</sup>.

60 ARE ABC-F gene *msrD* is a member of the *msr* (macrolide and streptogramin B  
61 resistant) gene group previously referred as *meI*<sup>21,22</sup>. This gene is generally found in operon  
62 with a macrolide efflux facilitator (*mefA* or *mefE*) *gene*, the two corresponding proteins acting  
63 synergistically to confer macrolide resistance<sup>23-26</sup>. This operon is part of the Macrolide Efflux  
64 Genetic Assembly (MEGA)<sup>27,28</sup> that disseminates in human pathogens on mobile genetic  
65 elements: conjugative transposons like the tn916-type<sup>29</sup> and conjugative prophages like the  
66  $\Phi$ 1207.3<sup>30</sup> among *Streptococci*, conjugative plasmids like the pMUR050<sup>31</sup> among

67 *Enterobacteria*. In *Streptococci*, the operon is transcribed in presence of erythromycin (ERY)  
68 as a polycistronic mRNA from a single promoter located ~350 bp upstream *mefA*<sup>32,33</sup>. It is also  
69 regulated by ribosome-mediated transcription attenuation via MefAL leader peptide  
70 (MTASMRLR), which is closely related to ErmDL leader peptide (MTHSMRLRFPTLNQ), both  
71 polypeptides harboring the characteristic macrolide-arrest motif Arg/Lys-X-Arg/Lys so called  
72 “+X+”<sup>14,33–35</sup>.

73 Here, we report the presence of a second transcriptional attenuator on the *mefA/msrD*  
74 operon regulating exclusively *msrD* expression upon macrolide exposure. Presence of ERY  
75 induces ribosome stalling on the previously identified *msrDL* leader peptide (encoding  
76 MYLIFM)<sup>34</sup>, allowing RNA polymerase (RNAP) to bypass an intrinsic terminator. Our findings  
77 demonstrate stalling occurs due to hampered translation termination on UAA stop codon,  
78 action of both release factors 1 and 2 (RF1 and RF2) being inhibited. Our results are supported  
79 by the cryo-EM structure of MsrDL-SRC that provides molecular insight on how the PTC  
80 precludes productive accommodation of RF1/RF2 and how the NC discriminates tunnel-bound  
81 cladinose-containing macrolides. The path of the NC within the tunnel greatly differs from  
82 previously described leader peptides<sup>12–16</sup> with the NC latching into a ribosomal crevice,  
83 conserved from prokaryotes to eukaryotes, delimited by 23S rRNA nucleotides U2584, U2586,  
84 G2608 and C2610 that may form a novel ribosomal functional site. Finally, our results  
85 demonstrate that the two ATPase sites of MsrD perform different functions and the protein can  
86 negatively self-regulate its synthesis in presence of ERY by direct action on MsrDL-stalled  
87 ribosomes.

88

## 89 RESULTS

### 90 MsrD provides macrolide and ketolide resistance by direct interaction with ribosome

91 The *mefA/msrD* macrolide resistance operon (Fig. 1a) is part of the MEGA element  
92 currently spreading among clinical isolates and livestock<sup>33,36–38</sup>. A phylogenetical analysis  
93 (Supplementary fig. 1a) shows that the operon disseminates predominantly in Gram-positive  
94 firmicutes (mostly *Streptococci*) and in some Gram-negative proteobacteria (such as

95 *Haemophilus influenzae*, *Neisseria gonorrhoeae* or *Escherichia coli*). Gene *msrD* shares ~62  
96 % identity with its closest homolog *msrE*<sup>7</sup>, both factors exhibiting the canonical ABC-F  
97 organization (Fig. 1b and Supplementary fig. 1b).

98 Model bacteria *Escherichia coli* (*E. coli*) presents undeniable advantages for genetic  
99 and molecular biology, but presence of multidrug efflux systems greatly limits its use in  
100 antibiotic research<sup>39,40</sup>. To circumvent this limitation, we took advantage of *E. coli* DB10 strain  
101 which exhibits exacerbated sensitivity toward macrolide antibiotics<sup>41</sup>. Heterologous expression  
102 of *msrD*<sub>WT</sub> from an arabinose-inducible promoter conferred macrolide and ketolide resistance  
103 phenotype to *E. coli* DB10 strain (Table 1), demonstrating the functionality of the factor in this  
104 organism. Expression of *msrD*<sub>WT</sub> resulted in 8-fold minimal inhibitory concentration (MIC)  
105 increase for 14-membered macrolide ERY, 8-fold for 15-membered macrolide azithromycin  
106 (AZI) and 2-fold for telithromycin (TEL, ketolide antibiotic derived from 14-membered  
107 macrolides). Similar results were reported for *Streptococcus pneumoniae* clinical isolates<sup>23</sup>.  
108 However, no change in MIC was observed for 16-membered macrolides tylosin (TYL) and  
109 spiramycin (SPI), neither for non-macrolide antibiotics lincomycin (LNC), linezolid (LNZ) and  
110 retapamulin (RTP) (Table 1).

111 Comparison of polysome profiles from bacteria unexposed or exposed to ERY show a  
112 stabilization of ribosome disomes (Fig. 1c, 1d and Supplementary fig. 1c) as expected for an  
113 antibiotic that inhibits ribosome elongation. The disome accumulation likely results from  
114 elongating ribosomes that collide on ERY-stalled ribosomes arrested at the beginning of the  
115 coding sequence. In presence of ERY ribosomes preferentially stall when they encounter “+x+”  
116 motifs which are present in the first 30 amino-acids of ~25% of *E. coli* proteins<sup>42,43</sup>. Expression  
117 of *msrD*<sub>WT</sub> alleviates the accumulation of disomes and restores a profile identical to that without  
118 ERY (Fig. 1d versus 1c and Supplementary fig. 1c). Western blots of the polysome fractions  
119 show an MsrD<sub>WT</sub> association with the 70S ribosome and the 50S subunit and polysomes (Fig.  
120 1d and Supplementary fig. 1c). These results agree with a model in which MsrD<sub>WT</sub> directly  
121 rescues ERY-stalled ribosomes and that MsrD can restore normal translation in presence of  
122 the antibiotic.

123 To understand the function of the ATPase activity of MsrD, we constructed ATPase-  
124 deficient variants MsrD<sub>E125Q</sub>, MsrD<sub>E434Q</sub> and MsrD<sub>E125Q/E434Q</sub> (hereafter referred as MsrD<sub>EQ2</sub>) by  
125 replacing the catalytic glutamic acid residue (E) in Walker B motif of each or both ABC domain  
126 by a glutamine (Q) (Fig. 1b and Supplementary fig. 1b). This mutation strongly reduces the  
127 ATP hydrolysis while preserving the local stereochemistry of active site and has been  
128 extensively used to trap ABC-F factors on the ribosome in ATP-bound conformation<sup>1-3,5,9</sup>.  
129 Expression of *msrD*<sub>EQ2</sub> in absence of ERY inhibits cell growth after OD<sub>600</sub>=0.4 and shows an  
130 accumulation of disomes on polysome profile (Supplementary fig. 1c) and western-blotting  
131 reveals its association with the 30S subunit, 70S ribosome and polyribosomes (Fig. 1d and  
132 Supplementary fig. 1c). These results shows that MsrD<sub>EQ2</sub> binds to the ribosome and inhibits  
133 its elongation as observed for most of the ABC-F carrying the E-to-Q mutation<sup>8,44</sup>. In presence  
134 of ERY, the disome and trisome accumulation increases and western blots show an increase  
135 of MsrD<sub>EQ2</sub> in the disome fraction (Fig. 1d and Supplementary fig. 1c). Still, the ATPase activity  
136 of MsrD impacts its binding preferences, MsrD<sub>WT</sub> interacting more with the 50S subunit in  
137 contrast to MsrD<sub>EQ2</sub> interacting more with the 70S ribosome (Fig. 1d and Supplementary fig.  
138 1c). Interestingly, the MsrD<sub>E125Q</sub> variant has an interaction profile with the ribosome similar to  
139 MsrD<sub>WT</sub> whether MsrD<sub>E434Q</sub> has one closer to MsrD<sub>EQ2</sub>.

140 A model consistent with these observations would imply that MsrD<sub>WT</sub> binds to ERY-  
141 stalled ribosomes in an ATP-bound close conformation without the need of its ATPase activity,  
142 then ATPase activity triggers 70S dissociation, MsrD<sub>WT</sub> staying associated with the 50S  
143 subunit. Similar results were observed by expressing *msrD*<sub>WT</sub> and *msrD*<sub>EQ2</sub> in *E. coli* K12  
144 MG1655 (Supplementary fig. 1d) in absence of ERY and with chloramphenicol being added to  
145 stabilize polysomes. They also show a decrease of the 70S peak correlated with an increase  
146 of 30S and 50S peaks for *msrD*<sub>WT</sub> condition when compared to the control, supporting the  
147 proposed dissociation model. Western blots show more MsrD<sub>EQ2</sub> than MsrD<sub>WT</sub> in soluble  
148 lysates (Supplementary fig. 1c) but MsrD<sub>EQ2</sub> inhibits protein synthesis including its own  
149 synthesis. Therefore, we hypothesized that MsrD<sub>EQ2</sub> is less expressed but more soluble, which  
150 has been confirmed with a solubility test (Supplementary fig. 1e).

151 We evaluated the influence of E-to-Q mutations of MsrD on bacterial growth and  
152 antibiotic resistance phenotype. All the mutations impair bacterial growth and antibiotic  
153 resistance phenotype (Fig. 1e), while MsrD<sub>E125Q</sub> and MsrD<sub>EQ2</sub> have a similar effect on bacterial  
154 growth in absence or at low ERY concentration, MsrD<sub>E434Q</sub> is more toxic. However, MsrD<sub>E125Q</sub>  
155 variant maintains some resistance (MIC = 4  $\mu$ M) compared to control (MIC = 2  $\mu$ M) which is  
156 also supported by the fact that MsrD<sub>E125Q</sub> IC<sub>50</sub> is ~8 times higher than Control IC<sub>50</sub> (Fig. 1e and  
157 Supplementary Table 1). These results together with polysome profile experiments (Fig. 1c,  
158 1d and Supplementary fig. 1d) suggest that interaction of MsrD with the 50S is necessary for  
159 antibiotic resistance mechanism.

160 The two ATP hydrolysis sites (Supplementary fig. 1b) have therefore different tasks  
161 and are functionally asymmetric, ATP site II achieving in part the mechanism of ERY-stalled  
162 ribosome rescue. We also evaluated the importance of other residues of MsrD. Truncation of  
163 the PtIM (replaced by three glycine) or just the Loop ( $\Delta$ PtIM,  $\Delta$ Loop respectively) completely  
164 abolished the resistance phenotype *in vivo* (Fig. 1f) as reported *in vitro* for MsrE<sup>7</sup>. Punctual  
165 mutations in the Loop (Fig. 1b) affect the resistance phenotype to a different extent, mutation  
166 of R241 into alanine has almost no effect on the phenotype, but equivalent mutation for L242  
167 or H244 reduces IC<sub>50</sub> by ~3 fold (Fig. 1g and Supplementary Table 1), demonstrating that these  
168 residues are important for MsrD function, but not essential even if they are predicted at the  
169 vicinity of the antibiotic (Supplementary fig. 1f) in the MsrE-ribosome complex<sup>7</sup>. Interestingly,  
170 this finding contrasts with mutagenesis assays for MsrE showing that mutation R241A reduces  
171 the resistance by more than 50%. Replacement of H244 by the larger residue tryptophan  
172 should displace the drug by steric occlusion, but the variant lost most of its antibiotic resistance  
173 phenotype (Fig. 1g). Similarly, MsrD<sub>WT</sub> does not provide resistance to TYL nor SPI (Table 1),  
174 while both antibiotics should clash with MsrD according to MsrE structure (Supplementary fig.  
175 1f). Same observation can be made with LNC, LNZ or RTP (Table 1 and Supplementary fig.  
176 1f). Therefore, MsrD action on the antibiotic is indirect and direct steric occlusion to displace  
177 the antibiotic seems excluded.

178



## 179 **Ribosome-mediated transcriptional attenuation regulates *msrD* expression**

180 Analysis of the *mefA/msrD* operon sequence exposes a stringent ribosome binding site  
181 (RBS, whose sequence is 5'-GGAGGA-3') only 8 bp downstream *mefA* stop codon and  
182 possibly required for translation of the downstream putative small ORF *msrDL* (Supplementary  
183 fig. 2a). In order to test the influence of *msrDL* on *msrD* expression, a fluorescent reporter,  
184 which contains the sequence spanning from the first nucleotide downstream *mefA* stop codon  
185 to *msrD* three first codons fused to the Yellow Fluorescent Protein gene (YFP), was cloned in  
186 the low copy pMMB plasmid<sup>45</sup> under the control of IPTG-inducible P<sub>LlacO-1</sub> promoter<sup>46</sup>. The  
187 resulting plasmid, pMMB-*msrDL-msrD*<sub>(1-3)</sub>:*yfp*, was used to directly follow the fluorescence  
188 reflecting *yfp* expression (Fig. 2a).

189 Basal fluorescence level was found stable in *E. coli* DB10 strain containing pMMB-  
190 *Control* independently of ERY concentration (Fig. 2a) while a fluorescence increase correlated  
191 with ERY concentration was observed in cells containing pMMB-*msrDL-msrD*<sub>(1-3)</sub>:*yfp*,  
192 indicating an ERY-dependent induction. Optimal induction was found at 100 nM ERY while  
193 only 6.25 nM was sufficient to significantly induce *msrD*<sub>(1-3)</sub>:*yfp* expression, demonstrating the  
194 high sensitivity of the system toward its inducer. A reduced, but significant fluorescence  
195 signal was detected at 0 nM ERY indicating an imperfect repression of the regulation .  
196 Inactivation of *msrDL* ORF by replacement of the start codon by an amber stop codon (pMMB-  
197 *msrDL*<sub>(no\_ORF)-msrD</sub><sub>(1-3)</sub>:*yfp*) resulted in the elimination of the fluorescence induction (Fig. 2a),  
198 demonstrating that *msrDL* translation is an important and necessary cis-acting feature to  
199 regulate *msrD*<sub>(1-3)</sub>:*yfp* expression as reported for *ermC*<sup>47</sup>.

200 In bacteria, antibiotic-dependent gene induction relies mainly on translational or  
201 transcriptional attenuation<sup>48</sup>. To determine if *msrDL* prompts a transcriptional or translational  
202 attenuation, northern blots analysis with a probe located in *msrD*<sub>(1-3)</sub>:*yfp* 3' UTR were performed  
203 on total RNA extracted from cell exposed or not to ERY and/or IPTG. A 1.2-kb band  
204 corresponding to *msrDL-msrD*<sub>(1-3)</sub>:*yfp* mRNA is transcribed in presence of IPTG and starts to  
205 increase steadily 5 min after exposure to 100 nM ERY (Fig. 2b). Consistent with this ERY-

206 dependent transcript accumulation, we concluded that *msrD* regulation by *msrDL* occurs at  
207 the transcription level.

208 Transcription attenuation employs premature transcription termination via: (i) Rho-  
209 dependent terminator (RDT) by binding of Rho factor, a RecA-type ATPase, to a C-rich and  
210 G-poor sequence known as Rho utilization site<sup>49</sup>; (ii) Rho-independent terminator (RIT) where  
211 a stable GC-rich stem-loop followed by a poly-uridine sequence causes RNAP to drop off<sup>50</sup>.  
212 Treatment with bicyclomycin, a Rho inhibitor, did not result in constitutive expression of the  
213 reporter, thus excluding the possibility of RDT attenuation (Supplementary fig. 2b). Analysis of  
214 the intergenic region between *msrDL* and *msrD* using ARNold server<sup>51</sup> revealed the presence  
215 of a RIT with a  $\Delta G$  of  $-7.9 \text{ kcal.mol}^{-1}$ . We also identified a consensus TTNTTT NusG-dependent  
216 RNAP pausing site embedded in *msrDL* sequence (Fig. 2c and Supplementary fig. 2a), as  
217 previously described for *vmIR*<sup>52,53</sup>. In order to test this possible transcription termination  
218 activity, we generated a mutant by removing the putative terminator (referred as pMMB-  
219 *msrDL*<sub>(no\_term)</sub>-*msrD*<sub>(1-3)</sub>:*yfp*). Deletion of the terminator resulted in a constitutive expression of  
220 the fluorescent reporter in absence of ERY, indicating that the terminator is a necessary cis-  
221 acting regulatory feature that can terminate transcription (Fig. 2c). These results validate the  
222 presence of a second transcriptional attenuator in the *mefA/msrD* operon that regulates  
223 exclusively *msrD*.

224

### 225 **Selective drug-sensing by MsrDL prevents its translation elongation and termination**

226 To determine how this regulation occurs via ribosome-mediated mechanism,  
227 translation of *msrDL* mRNA with the PURE system<sup>54</sup> was subjected to various antibiotics and  
228 its propensity to form SRC was analyzed by toeprinting<sup>55</sup> (Fig. 3 and Supplementary fig. 3). A  
229 strong toeprint signal was observed in presence of ERY and AZI, while it was absent in  
230 presence of TEL, TYL and SPI (Fig. 3a). This *in vitro* result is correlated to *in vivo* observations  
231 made with the *msrD*<sub>(1-3)</sub>:*yfp* reporter gene which was also only induced by ERY and AZI, but  
232 not by TEL, TYL, SPI and non-macrolide antibiotics (Fig. 3b).

233 We further characterized the translation of *msrDL* mRNA and showed that in presence  
234 of 50  $\mu$ M RTP, an inhibitor of the first peptide bond formation which allows to identify ORFs  
235 start codon<sup>56</sup>, a clear toeprint occurred (Fig. 3c). This toeprint corresponds to a ribosome  
236 stalled with the initiating codon in the ribosomal P site and confirms that ribosomes can initiate  
237 *msrDL* translation. The toeprint observed at positions +31, +32 and +33 relative to *msrDL* 5'  
238 end (Fig. 3a and 3c) in presence of ERY and AZI indicates an SRC located at the termination  
239 step of MsrDL synthesis with the C-terminal methionine (M6) codon in the P site and UAA stop  
240 codon in the A site. In accordance with this, reactions depleted of release factors (RF1, RF2,  
241 RF3) (Fig. 3c) show the same toeprint result. Moreover, addition of puromycin led to the loss  
242 of this toeprint signal, while preserving it in presence of ERY (Fig. 3c). Puromycin is an  
243 aminonucleoside antibiotic mimicking A site substrate tyrosyl-tRNA and causing premature  
244 chain termination. While actively translating ribosomes are sensitive to this antibiotic, stalled  
245 ones tend to be refractory<sup>15,16,20,57,58</sup>. The resistance of MsrDL-SRC to puromycin is consistent  
246 with an ERY-sensing NC that leads to PTC silencing and stalling. The stalled ribosome on  
247 ORF *msrDL* covers the first half of the hairpin of the RIT and therefore prevents its formation  
248 and transcription termination (Fig. 2c and Supplementary fig. 3).

249 The main dissimilarity between tested macrolides resides in the presence or absence  
250 of a cladinose moiety on C3 of the macrocyclic lactone ring which appears to be critical for  
251 MsrDL-SRC formation (Fig. 3a) similarly to ErmCL<sup>20,59</sup>. Absence of significant toeprint in  
252 presence of TEL (whose C3 cladinose sugar is replaced by a keto group) suggests that *msrDL*  
253 is translated efficiently without stalling. TYL and SPI differ from the other macrolides by the  
254 presence of disaccharide mycaminose-mycarose in place of the C5 monosaccharide  
255 desosamine. When bound to the ribosome, this extended sugar moiety protrudes into the PTC  
256 of the ribosome<sup>60</sup>. Absence of intermediate toeprint and increase of the toeprint corresponding  
257 to initiation complex in presence of these two drugs imply that these antibiotics stabilize the  
258 initiation complex. Previous results<sup>60-62</sup> have shown that they inhibit the formation of the  
259 peptide bond, our result suggests that it occurs mainly for the first peptide bond formation (Fig.  
260 3a).

261 We submitted the sequence of MsrDL to an alanine-scanning to investigate the  
262 importance of each residue and their ability to induce *msrD*<sub>(1-3)</sub>:*yfp* reporter, which indirectly  
263 reports the formation of an ERY-dependent SRC. The scan shows a strong reduction of  
264 inducibility for all the mutated residues with the exception Y2 (Fig. 3d). Since MsrDL is a  
265 hexapeptide, it is evident that most of the amino acids would have their importance to maintain  
266 a conformation able to sense ERY. A complete loss of inducibility has been observed for  
267 residues L3 and I4 suggesting that these two residues were directly involved in drug-sensing,  
268 which was structurally confirmed and detailed in the next section. Moreover, considering that  
269 MsrDL inhibits the action of both RF1/RF2 in presence of ERY, we mutated UAA stop codon  
270 into RF1-specific UAG and RF2-specific UGA stop codons to investigate a putative preferential  
271 inhibition as previously shown for TnaC<sup>63</sup>. Mutation of UAA into UAG or UGA reduces the level  
272 of inducibility of the reporter gene (Supplementary fig. 2c) demonstrating the importance of the  
273 stop codon. This observation is corroborated by our phylogenetic analysis which revealed a  
274 large prevalence of UAA stop codon among the different *msrDL* variants (Supplementary fig.  
275 2a). Most likely the UAA stop codon has been selected by evolution to maximize *msrD*  
276 expression in presence of an inducer. Mutagenesis of *msrDL* sequence by synonymous  
277 codons (iso-codons) as described in Methods leads to a reduction of the *yfp* expression for  
278 MsrDL<sub>WT-iso</sub> construct, possibly due to the lack of NusG pausing site, but the regulation is mostly  
279 preserved (Fig. 3d). Therefore, the amino acid composition of the peptide is responsible for  
280 the ribosome stalling. Addition of an extra alanine before the stop codon in MsrDL<sub>7A-iso</sub>  
281 construct reduces the regulatory potential of the leader peptide (Fig. 3d). Toeprinting assay  
282 reveals that this construct has two stalling positions: one occurs with the additional A7 codon  
283 in the ribosomal A site and the second with the stop codon in the A site (Fig. 3e). Thus, MsrDL  
284 peptide seems to induce efficient ribosomal stalling by preventing elongation and termination.  
285 When both are uncoupled like in the MsrDL<sub>7A-iso</sub> construct the regulation is less efficient (Fig.  
286 3d).

## 287 **Molecular mechanism of ribosome stalling by MsrDL**

288 To understand how MsrDL inhibits translation termination in presence of ERY, a  
289 synthetic mRNA containing a single *msrDL* copy was translated *in vitro* with purified *E. coli*  
290 DB10 ribosomes in presence of ERY as described in Supplementary fig. 4a and the resulting  
291 sample was subjected to cryo-EM. Single-particle reconstruction of MsrDL-SRC was done by  
292 refining two subclasses, one containing only P-tRNAs and one containing P- and E-tRNAs  
293 (respectively 11% and 28.1% of total particles), as described in Methods and on  
294 Supplementary fig. 4b. It resulted an initial map of 70S ribosome (EMD-13805) with an average  
295 resolution of 3.0 Å that was subjected to multibody refinement, generating reconstructions for  
296 the body and the head of the small subunit (EMD-13807 and EMD-13808) and the large  
297 subunit (EMD-13806), presenting average resolutions of 3.08, 3.3 and 2.97 Å respectively  
298 (Supplementary fig. 4b and 4c and Supplementary Table 2). The resolutions of the derived  
299 reconstructions were consistent with clear and unambiguous assignment of ribosomal proteins  
300 side chains, rRNA nucleotides and some post-transcriptional modifications (Supplementary  
301 fig. 4d to 4f). Local resolution of the codon-anticodon allowed unambiguous identification of  
302 the P-tRNA as an elongator  $_{Met}tRNA^{Met}$  (Supplementary fig. 4e), which is also confirmed by the  
303 presence of distinctive elements such as N<sup>4</sup>-acetylcytidine at position 34 (ac<sup>4</sup>C34) and N<sup>6</sup>-  
304 threonylcarbamoyladenine at position 37 (t<sup>6</sup>A37) (Supplementary fig. 4e and 4f)<sup>64,65</sup>,  
305 consistently with the toeprint results which assigned the M6 codon in the P site and UAA stop  
306 codon in the A site (Fig. 3c).

307 A clear density corresponding to ERY bound in its canonical position was found at the  
308 entrance of the NPET (Fig. 4a, 4b and Supplementary fig. 4d), allowing clear attribution of  
309 macrocyclic lactone ring, cladinose and desosamine sugars. A continuous density at the 3'  
310 end of P-tRNA extending within the entrance of ribosome tunnel was identified as MsrDL-NC  
311 and local resolution of ~3 Å allowed to model the peptide *de novo* (Fig. 4b and Supplementary  
312 fig. 4d). It adopts a hook-like shape with its N-terminal extremity protruding into a cavity at the  
313 entrance of the tunnel delimited by 23S rRNA nucleotides U2584, U2586, G2608 and C2610  
314 (Fig. 4b). One noticeable feature of MsrDL interaction with the ribosome is its residue Y2 that

315 bulges out the base U2584 to form a  $\pi$ -stacking with the base G2583 (Fig. 4c and 4d) in place  
316 of U2584. This unique interaction should stabilize the peptide conformation, while it appears  
317 structurally significant, it is not strictly essential since replacement of the Y2 by an alanine  
318 reduces by less than 50% the induction of the reporter gene (Fig. 3d). In addition, this residue  
319 is substituted in some MsrDL variants (Supplementary fig. 2a). MsrDL does not show  
320 numerous significant electrostatic interactions with the ribosome since it is mostly composed  
321 of hydrophobic amino acids. It is likely stabilized by hydrophobic interactions.

322 Our biochemical investigations showed that MsrDL-SRC was formed due to hampered  
323 translation termination on UAA stop codon. This stop codon is recognized by both RF1 and  
324 RF2 which subsequently catalyze peptide hydrolysis via their conserved GGQ motif protruding  
325 within the PTC. Structural alignment of our model to RF1- and RF2-containing ribosome  
326 structures<sup>66</sup> revealed that proper accommodation of the RFs is prevented by steric clashes of  
327 the methylated glutamine and the following glycines of the GGQ motif with the residue F5 of  
328 MsrDL and 23S rRNA bases U2584 and U2585 respectively (Fig. 4e). The conformation of  
329 MsrDL peptide stabilizes the PTC in an uninduced conformation<sup>67</sup> which prevents the opening  
330 of the active site necessary for peptide bond formation and hydrolysis (Fig. 4f). This  
331 observation suggests that MsrDL-SRC cannot catalyze peptide bond formation, as confirmed  
332 by the toeprinting performed on the MsrDL<sub>7A-iso</sub> construct (Fig. 3e). Structural alignment of  
333 MsrDL-SRC with ErmBL- and ErmCL-SRC demonstrates that 23S rRNA nucleotides U2506  
334 and 2585 are not in the same conformation (Supplementary fig. 5a and 5b), these bases in  
335 MsrDL-SRC being in a conformation more similar to ErmDL-, SpeFL- and TnaC(R23F)-SRC  
336 (Supplementary fig. 5c to 5e)<sup>12-16</sup>. However, unusual position of base U2584 seems to be a  
337 unique feature of MsrDL-SRC.

338 MsrDL may monitor the presence of cladinose-containing drugs as our *in vivo* and *in*  
339 *vitro* experiments suggested. Mutation of residues L3 and I4 abolished induction of the reporter  
340 gene suggesting that they were critical for drug recognition and/or conformation of the peptide  
341 (Fig. 3d). Consistently, in our model we identified residue L3 as the closest amino acid from  
342 cladinose moiety and residue I4 as the closest from desosamine moiety (Fig. 4b and 4g).

343 However, similarly to ErmBL, no close contact between the nascent chain and the drug was  
344 observed<sup>13,68</sup>, residue L3 being ~3.8 Å away from cladinose sugar and residue I4 being ~3.9  
345 Å away from desosamine sugar, consistently with a hydrophobic interaction between MsrDL  
346 and the drug (Fig. 4g to 4i). This observation is also corroborated by previous descriptions of  
347 pentapeptides conferring ERY resistance in which the presence of a leucine or isoleucine at  
348 position 3 was critical for drug recognition<sup>69,70</sup>. Moreover, the importance of 23S rRNA residue  
349 A2062 in acting as an ERY-sensor and in contributing to silence the PTC, has been  
350 demonstrated for some regulatory leader peptides<sup>71,72</sup>. In the case of ErmCL, the critical  
351 feature for macrolide-dependent stalling is the rotation of the base A2062 that forms an  
352 Hoogsteen base pairing with m<sup>2</sup>A2503<sup>12,71,72</sup>. The structure of MsrDL-SRC shows that residue  
353 I4 restrains rotation of base A2062 (Fig. 4j). Therefore, MsrDL induces an A2062/m<sup>2</sup>A2503-  
354 independent ribosome stalling<sup>72</sup>.

355 The path of MsrDL-NC within the ribosomal tunnel contrasts from all previous  
356 descriptions of elongating polypeptides (Fig. 4b and 5). Indeed, ERY-sensing ErmBL, ErmCL  
357 and ErmDL leader peptides<sup>12-14</sup> engage in the NPET and skirt around ERY, while MsrDL  
358 curves before encountering the ligand then engages into a dead-end crevice at the entrance  
359 of NPET (Fig. 4b and 5b). The same observation (Fig. 5c) can be made with metabolite-  
360 sensing SpeFL/TnaC(R23F) leader peptides<sup>15,16</sup> which avoid the crevice and enter the NPET.  
361 The first methionine of MsrDL-NC latches into the dead-end crevice which is delimited by 23S  
362 rRNA nucleotides U2584, U2586, G2608 and C2610 (Fig. 5a to 5c). This crevice located at  
363 the base of helix 93 (h93) is part of domain V of 23S rRNA and is conserved from bacteria to  
364 human (mitoribosome and cytosolic ribosome) (Fig. 5d, Supplementary fig. 5f and 5g). We  
365 named it proximal crevice.

366

### 367 **MsrD negatively regulates its own expression**

368 MsrD protein provides antibiotic resistance by rescuing ERY-stalled ribosome while  
369 *msrDL* translation in presence of ERY leads to the formation of a SRC. If MsrD is also able to  
370 rescue this SRC, it will repress its own expression and form a feedback loop similarly to Vga(A)

371 <sup>73</sup>. We tested this hypothesis using *E. coli* DB10 strains double transformed with pMMB-*msrDL-*  
372 *msrD*<sub>(1-3):yfp</sub> and the compatible pBAD plasmid expressing various *msrD* variants. Strains were  
373 grown in presence of ERY at 300 nM with their optical density and fluorescence monitored  
374 (Fig. 6a). Strain carrying the pBAD-*Control* showed high fluorescence and low OD<sub>600</sub> as  
375 observed in Fig. 2a, reflecting an induction of the reporter and a susceptibility to ERY. On the  
376 contrary, expression of *msrD* led to higher cell growth and a strong reduction of fluorescence  
377 which correspond respectively to antibiotic resistance and repression of the expression of the  
378 reporter. These results support that MsrD can rescue MsrDL-SRC and therefore releases the  
379 RIT repressing *msrD* transcription.

380 The strain expressing *msrD*<sub>E125Q</sub> has a low ERY resistance (Fig. 1e). When it is co-  
381 transformed with the pMMB-*msrDL-msrD*<sub>(1-3):yfp</sub> plasmid, no resistance is observed, possibly  
382 because the presence of the two plasmid creates some toxicity. Overall, the results show that  
383 MsrD variants that lost the ability to provide antibiotic resistance ( $\Delta$ PtIM,  $\Delta$ Loop and ATPase  
384 deficient mutants) also lost the ability to rescue MsrDL-SRC (Fig. 6a). Point mutations in the  
385 Loop of the PtIM indicated some discrepancy between antibiotic resistance phenotype and  
386 MsrDL-SRC rescue. All the mutants show an intermediary phenotype with less antibiotic  
387 resistance and less repression of reporter compared to MsrD. The mutant MsrD<sub>H244w</sub> has the  
388 same repression effect on the reporter than MsrD<sub>H244A</sub> for an equivalent OD<sub>600</sub> but it provides  
389 more than 3 times less antibiotic resistance (Fig. 1g and 6a). The mutant MsrD<sub>R241A</sub> which  
390 provides a resistance close to MsrD does not rescue the MsrDL-SRC as efficiently as the latter  
391 one (Fig. 1g and 6a). Mutants MsrD<sub>L242A</sub> and MsrD<sub>H244A</sub> provide similar resistance, but  
392 MsrD<sub>H244A</sub> confers a stronger repression of the reporter (Fig. 1g and 6a). Together these  
393 observations demonstrate that the determinants of the dual function of MsrD in conferring  
394 antibiotic resistance and rescuing MsrDL-SRC are overall similar.

395

## 396 DISCUSSION

397 We used genetic, molecular biology and structural approaches to dissect the regulation  
398 of streptococcal ARE ABC-F gene *msrD*, its effect on ERY-stalled ribosomes and to provide



399 information on ARE ABC-F mechanisms of action. We characterized the *msrDL* regulatory  
400 ORF which induces ribosome stalling in presence of cladinose-containing macrolides (Fig. 3,  
401 4 and 6b). Our structural data show that this inhibition results from the conjoint effects of: (i)  
402 MsrDL maintaining 23S rRNA bases U2506 and U2585 in an uninduced conformation (Fig.  
403 4f), (ii) the steric occlusion by U2584, U2585 and MsrDL residue F5 that precludes the  
404 productive accommodation of RF1/RF2 (Fig. 3c and 4e). MsrDL-stalled ribosome then  
405 hampers formation of a RIT allowing transcription of *msrD* (Fig. 2c, 3a, 3c and 6b). The  
406 coupling between translation and transcription necessary for this mechanism in *Streptococci*  
407 is possibly mediated by a NusG-dependent RNAP pausing site in *msrDL* (Fig. 2c).

408 MsrD binds with some specificity to ERY-stalled ribosome (Fig. 1d) and then its ATPase  
409 activity drives mechanical rearrangements to rescue stalled ribosome. The ATPase  
410 mechanism that allows the rescue is still unknown for ARE ABC-Fs and all the current  
411 structures of an ARE ABC-F in complex with the ribosome were generated with an ATPase-  
412 dead mutant<sup>1-3,5</sup> or use of non-hydrolysable ATP analogues<sup>7</sup>. These structures do not capture  
413 an antibiotic stalled complex and embodies a reaction intermediate before or after antibiotic  
414 release of an ARE ABC-F trapped on the ribosome. We provide here some evidence about  
415 possible mechanisms (Fig. 6b). We show that only one active ATPase site (Site II, MsrD<sub>E125Q</sub>)  
416 can provide some antibiotic resistance (Fig. 1e) while generating a strong toxicity for the cell  
417 independently of the antibiotic and also shows more association with 50S (Fig 1c and 1d). The  
418 mutant of Site II (MsrD<sub>E434Q</sub>) shows a stronger toxicity (Fig. 1e) and no antibiotic resistance,  
419 effects related to less dissociation from the ribosome (Fig. 1c and 1d). Therefore, it is possible  
420 that site I is needed for complete dissociation of MsrD from the ribosome or subunits after ATP  
421 hydrolysis occurs at site II. Mutation of both sites (MsrD<sub>EQ2</sub>) leads to the same toxicity as for  
422 inactive Site I (Fig. 1e), suggesting that having only Site II mutated induces a new MsrD  
423 conformation that inhibits more cell growth. In accordance with these results, independent E-  
424 to-Q mutations in the ARE ABC-F Vga(A), show that mutation in site I maintains an higher  
425 ATPase activity than mutation in site II<sup>74</sup>.

426 We envision two putative non-exclusive scenarios that involve for the first one, a  
427 disassembling of ERY-stalled ribosomes, and for the other one, a displacement of the drug  
428 followed by a restart of the translation process (Fig. 6b). A key point for future studies will be  
429 to explore the ATPase activity of MsrD in a stalled-ribosome context to determine how many  
430 rounds of ATP hydrolysis are necessary to rescue the latter one. The dissociation model  
431 requires the hydrolysis of only two ATP molecules, while antibiotic displacement may require  
432 multiple hydrolysis rounds in Site II to displace the drug and to position back the elongating  
433 peptide in a correct conformation in the NPET. So far, those experiments have been  
434 challenging due to the low solubility of all the ARE ABC-F proteins<sup>2,6</sup>.

435 Alongside with ErmBL, ErmCL and ErmDL, MsrDL constitutes the fourth ERY-sensing  
436 NC structurally described, however some mechanisms of drug-sensing and PTC silencing  
437 differ. First, similarly to ErmCL, the presence of C3 cladinose sugar is required for stalling (Fig.  
438 3a and 3b) contrary to ErmBL and ErmDL that senses drugs lacking this moiety such as  
439 oleandomycin, solithromycin or telithromycin<sup>12,14,59,68</sup>. Second, similarly to ErmBL, no close  
440 contact between the drug and MsrDL was observed (Fig. 4h and 4i)<sup>68</sup>. Third, MsrDL is the only  
441 described leader peptide that exploits inhibition of its hydrolysis by RFs to induce stalling in  
442 presence of antibiotic, similarly to the metabolite sensors TnaC and SpeFL<sup>15,16</sup>. On the  
443 contrary, ErmBL<sup>13</sup>, ErmCL<sup>12</sup> and ErmDL<sup>14</sup> employ only elongation inhibition. Fourth, ERY-  
444 dependent stalling on *msrDL* regulates downstream *msrD* via transcriptional attenuation (Fig.  
445 2b and 2c) while it relies on translational attenuation for ErmBL, ErmCL and ErmDL<sup>14,68,75</sup>.  
446 Finally, MsrDL-NC conformation and path within the ribosome greatly differ from previously  
447 described ligand-sensing leader peptides that elongate within the tunnel (Fig. 5b and 5c)<sup>12-16</sup>.  
448 It adopts a hook-like shape possibly due to hydrophobic interactions with the drug (Fig. 4b, 4g  
449 and 4h), while its initiating methionine engages in a dead-end crevice at the NPET entrance  
450 (Fig. 5). To our knowledge, this is the first description of this crevice, conserved in prokaryotes  
451 and eukaryotes (Supplementary fig. 5f and 5g), as a functional site within the ribosome and  
452 we propose to name it proximal crevice.

453 ARE ABC-F genes tend to be transcriptionally regulated as illustrated by *msrD*, *vmIR*,  
454 *vgaA*, *Imo0919* and *ImrC*<sup>52,73,76–78</sup>. However, MsrD can regulated its own expression by creating  
455 a negative feedback-loop which is not the case for VmIR<sup>52</sup>. The gene *msrD* forms an operon  
456 with the efflux pump *mefA* (Fig. 1a) which is also regulated *via* ribosome-mediated  
457 transcriptional attenuation, translational stalling occurring on *mefAL*<sup>33</sup>. Therefore, *msrD* is  
458 under the dual-regulation of two ERY-sensing leader peptides. One explanation for this  
459 redundancy may reside in the need for the bacteria to tightly regulate *msrD* because of its  
460 toxicity. Expression of *msrD*<sub>WT</sub> in *E. coli* DB10 led to a 20 % growth defect compared to control  
461 condition (Fig. 1e) suggesting that *msrD*<sub>WT</sub> expression has a fitness cost for the bacteria and  
462 can be beneficial only in presence of antibiotic. The presence of two attenuators creates a  
463 double-lock system to avoid any basal expression in absence of inducer and the negative  
464 feedback-loop maintains a minimal amount of MsrD production. Thus, as long as MefA can  
465 export enough antibiotic to provide resistance, *msrD* should be kept repressed. The fitness  
466 cost of the expression of ARE ABC-F genes is possibly the Achilles heel of bacteria containing  
467 those genes and may be exploited to fight antibiotic resistance. MsrD provides resistance to  
468 ERY, AZY and TEL<sup>23</sup> (Table 1) but only the first two induce its expression, indicating that MsrD  
469 can provide some resistance for an antibiotic which does not induce its expression. Thus,  
470 MsrDL facilitates the use of MsrD by the bacteria and maintains its evolution under its control.  
471

472 **ACKNOWLEDGMENTS**

473 This work has benefited from the facilities and expertise of the Biophysical and Structural  
474 Chemistry platform (BPCS) at IECB, CNRS UMS3033, Inserm US001, University of Bordeaux.  
475 C.R.F. is funded by a doctoral grant from the french Ministère de l'Enseignement supérieur,  
476 de la Recherche et de l'Innovation, F.O. and G.B. have received support from the LABEX  
477 program (DYNAMO ANR-11-LABX-0011), and the ANR grants EZOtrad (ANR-14-ACHN-  
478 0027) for G.B. and ABC-F\_AB (ANR-18-CE35-0010) for G.B. and Y.H., ERC-2017-STG  
479 #759120 "TransTryp" to Y.H. E.C.L. and C.A.I. have received funding for this project from the  
480 European Research Council (ERC) under the European Union's Horizon 2020 research and  
481 innovation program (Grant Agreement No. 724040). Authors would like to thank Dr. Olivier  
482 Chesneau (Département de Microbiologie, Institut Pasteur, Paris - France) for providing *E. coli*  
483 DB10 strain, plasmids pBAD33 and pVN50; Dr. Sylvain Durand and Dr. Maud Guillier (UMR  
484 8261, CNRS, Université de Paris, Institut de Biologie Physico-Chimique, Paris - France) that  
485 kindly provided respectively bicyclomycin and equipment for toeprinting experiments. Authors  
486 would like also to thank Laura Monlezun and Tina Wang for proofreading the manuscript.

487

488 **AUTHOR CONTRIBUTIONS**

489 F.O. performed the first experiments that initiated the project. C.R.F. performed most of the  
490 experiments. S.N. performed northern blotting experiments. C.R.F. prepared the cryo-EM  
491 sample. H.S. prepared cryo-EM grids and imaged them. C.A.I. and Y.H. processed cryo-EM  
492 data. C.R.F. and E.C.L. reconstructed the atomic model. G.B. initiated the project and designed  
493 the research program with Y.H. C.R.F. and G.B. wrote the paper with input from all authors.

494

495 **DECLARATION OF INTERESTS**

496 The authors declare no competing interests. Requests for materials should be addressed to  
497 G.B. (boel@ibpc.fr).

498 **MAIN FIGURE TITLES AND LEGENDS**

499 **Figure 1. Translation factor MsrD alleviates erythromycin effects upon translation *in***  
500 ***vivo*.** (a) Organization of the *mefA/msrD* macrolide resistance operon. In presence of ERY,  
501 ribosomes stall during translation of *mefAL* leading to transcription anti-attenuation, both *mefA*  
502 and *msrD* being then transcribed. Similar mechanism occurs during translation of *msrDL*,  
503 which regulates transcription of *msrD* only. (b) Sequence alignment of various *msr* homologs  
504 visualized with Jalview according to percentage of identity. Positions of tested mutations are  
505 highlighted in red and indicated by arrows. Main features of ABC-F proteins are indicated on  
506 the schematic. Genebank accession numbers are indicated between brackets. See also  
507 Supplementary Fig. 1b. (c and d) Polyribosomes analysis and western blotting of *E. coli* DB10  
508 expressing a control (pBAD-*Control*), *msrD*<sub>WT</sub> (pBAD-*msrD*<sub>WT</sub>), *msrD*<sub>EQ2</sub> (pBAD-*msrD*<sub>EQ2</sub>),  
509 *msrD*<sub>E125Q</sub> (pBAD- *msrD*<sub>E125Q</sub>) or *msrD*<sub>E434Q</sub> (pBAD- *msrD*<sub>E434Q</sub>) untreated or treated for 1 h with  
510 25 μM ERY during mid-log phase. “L” stands for total lysate. See also Supplementary fig. 1c  
511 and 1d and Methods. (e to g) Relative growth of *E. coli* DB10 expressing *msrD* variants in  
512 presence of ERY after 24 h. Optical densities were normalized relative to optical densities of  
513 *E. coli* DB10 pBAD-*Control* grown in the absence of ERY. Error bars represent mean ± s.d. for  
514 triplicate experiments. See also supplementary Table 1.

515

516 **Figure 2. Erythromycin-dependent transcriptional attenuation regulates *msrD***  
517 **expression.** (a) ERY-dependent induction of *msrD*<sub>(1-3)</sub>:*yfp*. Fluorescent reporters shown on  
518 schematics have been introduced in *E. coli* DB10 and grew in presence of 1 mM IPTG and  
519 increasing sublethal ERY concentrations during 17 h. Fluorescence has been plotted against  
520 OD<sub>600</sub>, error bars for both axes represent mean ± s.d. for triplicate experiments. (b) Northern  
521 analysis of *msrD* transcript. RNAs were extracted before adding or not 1 mM IPTG (T<sub>0</sub>), 10  
522 min after adding IPTG (T<sub>10</sub>), and 5, 15, 30, 60, 120 min after adding or not 100 nM ERY.  
523 Location of probe in *msrD*<sub>(1-3)</sub>:*yfp* 3' UTR is shown on the schematic. The presence of a second  
524 band was also observed but we hypothesized that it was abortive transcript resulting from the  
525 construct insofar as its presence correlates with induction by IPTG and ERY, and is no longer  
526 detectable using other probes (data not shown). Note the presence of leaky transcription in  
527 absence of IPTG, that is slightly amplified in presence of ERY. (c) Deletion of the intrinsic  
528 terminator between *msrDL* and *msrD*<sub>(1-3)</sub>:*yfp* leads to a constitutive induction in absence of  
529 ERY. Error bars for both axes represent mean ± s.d. for triplicate experiments.

530

531 **Figure 3. MsrDL is a macrolide-sensing nascent chain that stalls the ribosome.** (a)  
532 Toeprinting assay of *msrDL* in the absence (-) or in the presence of 50 μM of various macrolide  
533 antibiotics. White arrow indicates initiation codon. Black arrows indicate ribosome stalling, with  
534 M6 codon in the P site. Chemical structure of antibiotics is shown, C3 cladinose sugar of ERY

535 and AZI being highlighted. See also Supplementary fig. 3. (b) *In vivo* induction of *msrD*<sub>(1:3):yfp</sub>  
536 by various PTC/NPET targeting antibiotics. Bacteria containing pMMB-*msrDL*-*msrD*<sub>(1:3):yfp</sub>  
537 were grown during 17 h in presence of 1 mM IPTG, in the absence (grey histograms) or in the  
538 presence of 50 nM antibiotics (red histograms). Error bars represent mean  $\pm$  s.d. for triplicate  
539 experiments. (c) Toeprinting assay depleted of release factors was performed in the absence  
540 of ribosome (line 1), in presence of 50  $\mu$ M RTP to assess start codon (line 2), without or with  
541 50  $\mu$ M ERY (line 3 and 4), without or with 50  $\mu$ M ERY then supplemented with 100  $\mu$ M  
542 puromycin (line 5 and 6), without or with 50  $\mu$ M ERY in presence of RF1/RF2/RF3 (line 7 and  
543 8). The schematic indicates position of toeprint signal on the synthetic mRNA, P site codon of  
544 MsrDL-SRC is underlined. See also Supplementary fig. 3. (d) Effects of *msrDL* variants on the  
545 expression of *msrD*<sub>(1:3):yfp</sub>. Bacteria were grown during 17 h in presence of 1 mM IPTG, in the  
546 absence (grey histograms) or in the presence of 100 nM ERY (red histograms). Error bars  
547 represent mean  $\pm$  s.d. for triplicate experiments, square boxes show fold of induction. (e)  
548 Toeprinting assay performed on the MsrDL<sub>7A-iso</sub> construct in absence or presence of ERY.  
549 Addition of a sense codon after M6 codon leads to translational arrest with M6 codon in the P  
550 site (grey arrows) and A7 codon in the A site in presence of ERY. A faint toeprint is also  
551 observed with A7 codon in the P site (black arrows) and the stop codon in the A site.

552

553 **Figure 4. Structure of MsrDL-SRC.** (a) Transverse section of the cryo-EM map showing the  
554 30S (grey) and 50S (white) ribosomal subunits, mRNA (purple), ERY (red) and MsrDL-NC  
555 (gold) bound to P-site tRNA<sup>Met</sup> (beige). (b) Close-up of MsrDL-NC within ribosomal tunnel  
556 showing experimental density and modelled structure, colored as Fig. 4A while 23S rRNA  
557 nucleotides are shown in light grey. (c and d) Presence of MsrDL residue Y2 displace  
558 nucleotide U2584 out of its position when compared to RF1- (PDB 5J30, light blue) and RF2-  
559 containing (PDB 5CZP, blue) termination complex, thus forming a  $\pi$ -stacking with G2583<sup>66</sup>.  
560 (e) Conformation of U2584 and U2585 prevent productive accommodation of RF1 (PDB 5J30,  
561 light blue) and RF2 (PDB 5CZP, blue) while catalytic methylated glutamine would clash with  
562 MsrDL residue F5<sup>66</sup>. (f) PTC in MsrDL-SRC (light grey) is stabilized in an uninduced state (PDB  
563 1VQ6, pink) rather than in an induced state (PDB 1VQN, green) as U2585 is pushed back by  
564 MsrDL residue Y2<sup>67</sup>. (g to i) Molecular basis for C3 cladinose sugar recognition by MsrDL.  
565 Residue L3 is at proximity of cladinose sugar while residue I4 is at proximity of desosamine  
566 sugar. TEL lacking cladinose sugar and failing to form MsrDL-SRC has been aligned (PDB  
567 4V7S)<sup>79</sup>. (j) Presence of residue I4 avoids rotation of A2062 to form an Hoogsteen base pairing  
568 with m<sup>2</sup>A2503 as it is the case for ErmCL-SRC (PDB 3J7Z, green)<sup>12</sup>. Light blue dashed lines  
569 indicate hydrogen bonds formed by Hoogsteen base pairing. For the whole figure, structures  
570 were aligned on domain V of 23S rRNA. Spheres represent van der Waals radii.

571

572 **Figure 5. MsrDL engages in a conserved crevice at the NPET entrance.** (a) Secondary  
573 structure of the *E. coli* 23S rRNA domain V showing location of the proximal crevice at the  
574 base of h93. For the whole figure, nucleotides delimitating proximal crevice are shown in red.  
575 (b and c) Comparison of MsrDL path (gold) with ERY-dependent leader peptides ErmBL (PDB  
576 5JTE, blue), ErmCL (PDB 3J7Z, green), ErmDL (PDB 7NSO, teal) as well as L-ornithine-  
577 sensing SpeFL (PDB 6TC3, pink) and L-tryptophan-sensing TnaC(R23F) (PDB 7O1A,  
578 purple)<sup>12-16</sup>. See also Supplementary fig. 5a to 5e. (d) Proximal crevice in domain V is  
579 conserved from bacteria to human (MsrDL-SRC, grey; *S. aureus* PDB 6YEF, light green; *H.*  
580 *sapiens* 55S mitoribosome PDB 7A5F, light blue; *H. sapiens* 80S ribosome PDB 6OLI, marine  
581 blue)<sup>80-82</sup>. See also Supplementary fig. 5g and 5h. For the whole figure, atomic model of MsrDL  
582 is shown with its experimental density. Structures were aligned on domain V of 23S rRNA.

583

584 **Figure 6. MsrD negatively regulates its own synthesis upon erythromycin exposure.** (a)  
585 Effects of MsrD variants on MsrDL. *E. coli* DB10 containing pMMB-*msrDL-msrD*(1-3):*yfp* and  
586 expressing various *msrD* mutants were grown in presence of 0.2 % L-Arabinose, 1 mM IPTG  
587 and 300 nM ERY, both OD<sub>600</sub> and fluorescence being recorded over 24 h. Fluorescence has  
588 been plotted against OD<sub>600</sub>, error bars for both axes represent mean  $\pm$  s.d. for triplicate  
589 experiments. Color code is same as Fig. 1e to 1g. Light green rectangle indicates bacterial  
590 growth over control plasmid. (b) Model of MsrD regulating its own expression and providing  
591 antibiotic resistance. Presence of a NusG-dependent pause site may stall the RNAP and  
592 provides explanation why the system works in bacteria where transcription and translation are  
593 not so tightly coupled. In absence of ERY, RNAP drops off at Rho-independent transcription  
594 terminator. In presence of ERY, the ribosome following the RNAP (presumably paused) stalls  
595 and unwinds the terminator leading to *msrD* transcription. Once translated, MsrD negatively  
596 regulates its own expression on one side, and provides antibiotic resistance on the other side.  
597 ATP-bound MsrD recognizes ERY-stalled ribosome and may either expel the antibiotic or  
598 dissociate the ribosome, ATP site II being active. Activity in ATP site I may lead to MsrD  
599 dissociation and recycling.

600 **MAIN TABLE TITLES AND LEGENDS**

601 **Table 1. Minimum inhibitory concentration (MIC) and half maximal inhibitory**  
602 **concentration (IC<sub>50</sub>) of *E. coli* DB10 expressing *msrD* in presence of ribosome-targeting**  
603 **antibiotics. See Methods for experimental details.**

604

605

Antibiotic	pBAD- <i>Control</i>		pBAD- <i>msrD</i> <sub>WT</sub>	
	MIC (μM)	IC <sub>50</sub> (μM)	MIC (μM)	IC <sub>50</sub> (μM)
Erythromycin	2	0,179 ± 0,007	16	4,592 ± 0,582
Azithromycin	0.25	0,046 ± 0,002	2	0,953 ± 0,053
Telithromycin	1	0,086 ± 0,008	2	0,714 ± 0,066
Tylosin	4	1,649 ± 0,151	4	1,672 ± 0,103
Spiramycin	2	0,758 ± 0,063	2	0,81 ± 0,078
Lincomycin	32	12,61 ± 2,154	32	12,62 ± 1,27
Linezolid	32	13,62 ± 2,064	32	13,41 ± 1,137
Retapamulin	1	0,071 ± 0,004	1	0,075 ± 0,007



## 606 **METHOD DETAILS**

### 607 **Construction of plasmids**

608 Strains and plasmids used in this study are listed in Supplementary Table 3. Oligonucleotides  
609 are listed in Supplementary Table 4. For the whole study, the considered reference sequence  
610 for *mefA/msrD* macrolide resistance operon was a Tn916-type transposon inserted in  
611 *Streptococcus pneumoniae* strain 23771 genome (Genbank accession number  
612 FR671415.1)<sup>83</sup>. Plasmids pBAD-*Control* and pBAD-*msrD*<sub>WT</sub> containing a C-terminal  
613 hexahistidine tag (originally referred as pBAD33 and pVN50) were kindly retrieved from Olivier  
614 Chesneau at Institut Pasteur (Paris, France)<sup>24</sup>. Both *mefA/msrD* macrolide resistance operon  
615 and pBAD-*msrD*<sub>WT</sub> encode the same protein MsrD (Uniprot accession number A0A496M710).

616

617 **pBAD plasmids.** Those plasmids allow a tight and stringent expression control via catabolite  
618 repression, interest gene being repressed in presence of 0.4 % (w/v)  $\beta$ -D-Glucose and induced  
619 in presence of 0.2 % (w/v) L-Arabinose. Transformed clones were selected with 20  $\mu$ g.ml<sup>-1</sup>  
620 chloramphenicol. In this study, all *msrD* mutants contain a C-terminal hexahistidine tag.  
621 Catalytic mutant *msrD*<sub>EQ2</sub> was generated by amplifying pBAD-*msrD*<sub>WT</sub> with primer pairs 5/6 and  
622 7/8, both fragments being assembled with NEBuilder HiFi DNA Assembly Master Mix (New  
623 England Biolabs). Catalytic mutants *msrD*<sub>E125Q</sub>, *msrD*<sub>E434Q</sub> were generated via quickchange  
624 mutagenesis with primers pairs 9/10 and 11/12. Mutants *msrD* <sub>$\Delta$ Loop</sub> and *msrD* <sub>$\Delta$ PtIM</sub> were  
625 generated based on phylogenetic alignments by deleting residues between K216/K254 and  
626 E189/A274 respectively, a three-glycine linker being added to allow flexibility, via quickchange  
627 mutagenesis using primer pairs 13/14 and 15/16. Variants *msrD*<sub>R241A</sub>, *msrD*<sub>L242A</sub>, *msrD*<sub>H244A</sub>,  
628 *msrD*<sub>H244W</sub> were generated via fusion PCR by amplifying *msrD*<sub>WT</sub> with primers pairs 1/18, 1/20,  
629 1/22, 1/24 and 2/17, 2/19, 2/21, 2/23 respectively. Backbone was amplified with primer pair  
630 3/4 and fragments were assembled with NEBuilder HiFi DNA Assembly Master Mix (New  
631 England Biolabs).

632 **pMMB plasmids.** All pMMB constructs originated from a low copy IPTG-inducible plasmid  
633 pMMB67EH-*yfp*, consisting in original pMMB67EH<sup>45</sup> containing optimized *venus-yfp*  
634 enhancing its translation under the control of P<sub>tac</sub> promoter (manuscript in preparation).  
635 Transformed clones were selected with 100  $\mu$ g.ml<sup>-1</sup> ampicillin. To test *msrDL* functions *in vivo*,  
636 several fluorescent reporter genes have been designed. First, pMMB67EH-*yfp* native P<sub>tac</sub>  
637 promoter was replaced by P<sub>LlacO-1</sub> promoter as previously described<sup>46</sup>:

638 5'- ATAAATGTGAGCGGATAACATTGACATTGTGAGCGGATAACAAAGATACTGAGCACA -  
639 3' (lac operators, shaded grey; transcription start, bold). This IPTG-inducible promoter allows  
640 a tight and stringent transcription regulation compared to P<sub>tac</sub> promoter, insofar as no regulatory  
641 element is found in the 5' UTR. Promoter was replaced by amplifying pMMB67EH-*yfp* with  
642 primer pairs 25/26, PCR fragment being then re-circularized via NEBuilder HiFi DNA Assembly

643 Master Mix (New England Biolabs). The resulting plasmid was named pMMBpLlacO-1-67EH-  
644 *yfp*. Plasmid pMMB-*msrDL-msrD*<sub>(1-3)</sub>:*yfp* has been designed by introducing the sequence  
645 spanning from the first nucleotide downstream *mefA* stop codon to *msrD* three first codons  
646 fused to *yfp*. The introduced sequence is as follows: 5'-  
647 ACAATATT**GGAGGA**AATATTTATGTATCTTATTTTCATGTAACTCTTCCTGCTAAAATCGCA  
648 GGGTTTTCCCTGCATACAAGCAAATGAAAGCATGCGATTATAGACAG**GGAGGAAATGTTA**  
649 TGGAATTA-3' (RBS, bold; *msrDL*, shaded grey, *msrD* three first codons are underlined). To  
650 clone such construct, *yfp* gene was amplified from pMMB67EH-*yfp* with primer pairs 27/29  
651 then with 28/29 to generate the insert, backbone was amplified with primer pair 30/31 using  
652 pMMBpLlacO-1-67EH-*yfp* as matrix, both fragments being then assembled with NEBuilder  
653 HiFi DNA Assembly Master Mix (New England Biolabs). Plasmid pMMB-*control* was built by  
654 removing the *msrDL-msrD*<sub>(1-3)</sub>:*yfp* cassette via quickchange mutagenesis using primer pair  
655 32/33, the resulting construction containing only the P<sub>LlacO-1</sub> promoter followed by the plasmid  
656 endogenous *rrnB* transcription terminator. Plasmid pMMB-*msrDL*<sub>(no\_term)</sub>-*msrD*<sub>(1-3)</sub>:*yfp* (where  
657 the RIT between *msrDL* and *msrD* is deleted) was generated by amplifying pMMB-*msrDL*-  
658 *msrD*<sub>(1-3)</sub>:*yfp* with primer pair 34/35, PCR fragment being then re-circularized via NEBuilder  
659 HiFi DNA Assembly Master Mix (New England Biolabs). The various *msrDL* mutants were  
660 cloned via quickchange mutagenesis by amplifying pMMB-*msrDL-msrD*<sub>(1-3)</sub>:*yfp* with primers  
661 36 to 51. Plasmid pMMB-*msrDL*<sub>(MYLIFMA-isocodons)</sub>-*msrD*<sub>(1-3)</sub>:*yfp* was generated by replacing  
662 *msrDL*<sub>WT</sub> sequence (ATGTATCTTATTTTCATGTAA) by a recoded sequence  
663 (ATGTACCTGATCTTCATGGCCTAA) using isocodons and introducing an extra alanine  
664 codon (7A codon) before stop codon. Sequence was recoded using isocodons because  
665 mutating the WT sequence introduced a new promoter. To do so, pMMB-*msrDL-msrD*<sub>(1-3)</sub>:*yfp*  
666 was amplified with primer pair 52/53, PCR fragment being then re-circularized via NEBuilder  
667 HiFi DNA Assembly Master Mix (New England Biolabs). Recoded sequence without the 7A  
668 codon (ATGTACCTGATCTTCATGTAA) was generated via quickchange mutagenesis by  
669 amplifying pMMB-*msrDL*<sub>(MYLIFMA-isocodons)</sub>-*msrD*<sub>(1-3)</sub>:*yfp* with primer pair 54/55, leading to plasmid  
670 pMMB-*msrDL*<sub>(WT-isocodons)</sub>-*msrD*<sub>(1-3)</sub>:*yfp*.

671

## 672 **Antibiotic susceptibility testing, MIC and IC50 determination**

673 A saturated preculture of *E. coli* DB10 transformed with pBAD plasmid was grown overnight at  
674 37 °C under vigorous shaking in Luria-Bertani Miller broth (LB), 20 µg.ml<sup>-1</sup> chloramphenicol  
675 and supplemented with 0.4 % (w/v) β-D-Glucose. Antibiotic susceptibility testing assay was  
676 performed in Mueller-Hinton broth (MH, Sigma Aldrich), antibiotics being diluted via serial  
677 dilutions. A 96-wells flat-bottom plate (Flacon) was filled with a final volume per well of 200 µl,  
678 containing 20 µg.ml<sup>-1</sup> chloramphenicol and 0.2 % (w/v) L-Arabinose and antibiotic to test. Wells  
679 were inoculated at OD<sub>600</sub> ~0.03-0.04 prior to addition of 60 µl mineral oil (Sigma Aldrich)

680 avoiding evaporation but not oxygen diffusion. Plates were therefore incubated for 24 h in  
681 CLARIOstar Plus plate reader (BMG Labtech) at 37 °C with 600 rpm double-orbital shaking,  
682 OD<sub>600</sub> being measured each 30 min. Optical densities at 24 h were then normalized relative to  
683 optical densities of *E. coli* DB10 pBAD-*Control* grown in the absence of antibiotic in Prism  
684 7(GraphPad). MIC was determined as absence of growth compared to blank, IC50 was  
685 calculated in Prism using equation  $Y=Bottom + (Top-  
686 Bottom)/(1 + ((X^{HillSlope})/(IC50^{HillSlope})))$  and the standard deviation was calculated by  
687 multiplying standard error by square root of n (n being at least 3 replicates). To generate  
688 curves, for bacteria grown in absence of antibiotic (0 μM), since coordinates are plotted as  
689 logarithms and since log(0) is undefined, this point has been approximated 2 log units below  
690 the lowest tested value (*i.e.* 0.0625 μM) consistently with Prism user guide<sup>84</sup>. Curve fitting was  
691 performed with non-linear fitting function “log(inhibitor) vs. response -- Variable slope” using  
692  $Y=Bottom + (Top-Bottom)/(1+10^{((LogIC50-X)*HillSlope)})$ . Both equations gave strictly the  
693 same result for IC<sub>50</sub>.

694

### 695 ***In vivo* induction assay**

696 A saturated preculture of *E. coli* DB10 transformed with pMMB plasmid was grown overnight  
697 at 37 °C under vigorous shaking in LB with 100 μg.ml<sup>-1</sup> ampicillin. For bacteria double-  
698 transformed with pMMB and pBAD plasmids, media was also supplemented with 20 μg.ml<sup>-1</sup>  
699 chloramphenicol and supplemented with 0.4 % (w/v) β-D-Glucose. *In vivo* induction assay was  
700 performed in Mueller-Hinton broth (MH, Sigma Aldrich). A 96-wells flat-bottom plate (Flacon)  
701 was filled with a final volume per well of 200 μl, containing 100 μg.ml<sup>-1</sup> ampicillin, 1 mM  
702 Isopropyl β-D-1-thiogalactopyranoside (IPTG). Growth medium was supplemented with 20  
703 μg.ml<sup>-1</sup> chloramphenicol and 0.2 % (w/v) L-Arabinose if pBAD plasmid is present. Induction of  
704 fluorescent reporters being antibiotic-dependent, growth media were supplemented with  
705 required antibiotic accordingly. Plates were therefore incubated in CLARIOstar Plus plate  
706 reader (BMG labtech) at 37 °C with 600 rpm double-orbital shaking up to 24 h, OD<sub>600</sub> and  
707 fluorescence (excitation: 497-15 nm, emission: 540-20 nm, gain 1600) being measured each  
708 30 min.

709

### 710 **Polyribosomes fractionation**

711 Saturated precultures of *E. coli* DB10 transformed with pBAD-*control*, pBAD-*msrD*<sub>WT</sub>, pBAD-  
712 *msrD*<sub>EQ2</sub>, pBAD-*msrD*<sub>E125Q</sub> or pBAD-*msrD*<sub>E434Q</sub> were grown overnight at 37 °C under vigorous  
713 shaking in LB, 20 μg.ml<sup>-1</sup> chloramphenicol, 0.4 % (w/v) β-D-Glucose. Growth media (MH, 20  
714 μg.ml<sup>-1</sup> chloramphenicol, 0.2 % (w/v) L-Arabinose) was inoculated at OD<sub>600</sub>=0.05 with  
715 normalized precultures, and cells were grown at 37 °C and 180 rpm. When OD<sub>600</sub>=0.5 was  
716 reached, cultures were divided in two and one half was treated with a 25 μM erythromycin.

717 Cultures were then incubated 1 hour at 37 °C and 180 rpm before harvesting. Cultures were  
718 chilled and cells were harvested by centrifuging 10 min at 8 000 rpm, 4 °C. Supernatant was  
719 discarded and cells were resuspended in 350 µl of lysis buffer (20 mM Tris pH 8, 20 mM MgCl<sub>2</sub>,  
720 100 mM NH<sub>4</sub>(OAc), 2 mM β-mercaptoethanol, 1 mg.ml<sup>-1</sup> lysozyme) and transferred in  
721 microtubes. Then, 30 µl of sodium deoxycholate 10 % (w/v) was added and cells were  
722 mechanically lysed by 3 rounds of freezing-thawing. Lysates were clarified by centrifuging 20  
723 min at 18 000 xg, 4 °C and total RNAs were quantified. Finally, 500 µg of total RNAs were  
724 loaded onto 10-40 % (w/v) sucrose gradients (20 mM Tris pH 8, 20 mM MgCl<sub>2</sub>, 100 mM  
725 NH<sub>4</sub>(OAc), 2 mM β-mercaptoethanol) and centrifuged 2 h at 40 000 rpm, 4 °C in SW41 rotor  
726 (Beckman Coulter). Samples were fractionated and collected using Biocomp Piston Gradient  
727 Fractionator (BioComp Instruments), absorbance being measured at 254 nm.

728

### 729 **Immunoblotting**

730 Fractions of 400 µl were precipitated in ice-cold absolute ethanol (1 volume of sample, 3  
731 volumes of ethanol) overnight at -20 °C. Samples were then centrifuged 45 min at 18 000 xg,  
732 4 °C. Supernatant was removed and samples were vacuum-dried. Pellets were resuspended  
733 in 33.3 µl 1X Laemmli buffer, 10 µl being loaded on 12.5 % acrylamide SDS-PAGE gels.  
734 Concerning total lysates, 10 µg of normalized total RNAs were loaded as control. Gels were  
735 resolved by migrating at 0.04 A and then applied on Immun-Blot PVDF membrane (Bio-Rad)  
736 that had been activated in absolute ethanol then washed in electro-transfer buffer (25 mM Tris  
737 base, 192 mM glycine, 0.1 % (w/v) SDS, 10 % (v/v) absolute ethanol). Proteins were electro-  
738 transferred at 100 V during 1 h. Membranes were blocked by incubating 1 h in 1X PBS  
739 supplemented with 0.5 % nonfat dry milk then washed with 1X PBS. C-term His-tagged MsrD<sub>WT</sub>  
740 and MsrD<sub>EQ2</sub> were detected using anti-6xHis-tag primary antibody (Covalab, 1:2 000 dilution  
741 in 1X PBS, 0.1 % Tween-20) combined with anti-mouse-HRP secondary antibody (Covalab,  
742 1:20 000 dilution in 1X PBS, 0.1 % Tween-20). Immunoblots were revealed by performing an  
743 ECL detection using Clarity Western ECL Substrate (Bio-Rad) and imaged with Li-Cor  
744 Odyssey FC imaging system (Li-Cor).

745

### 746 **Preparation of *E. coli* DB10 ribosomes**

747 An overnight saturated *E. coli* DB10 preculture was used to inoculate growth medium (LB,  
748 dilution 1:100) and cells were grown at 37 °C and 180 rpm. When OD<sub>600</sub>=0.5, cells were  
749 washed and harvested by two centrifugations during 20 min, 5 000 xg at 4°C followed by  
750 resuspensions in Buffer A (20 mM Tris pH 7.4, 10 mM Mg(OAc), 100 mM NH<sub>4</sub>(OAc), 0.5 mM  
751 EDTA). Pellets were resuspended in Buffer A supplemented with 6 mM β-mercaptoethanol,  
752 10 mg.ml<sup>-1</sup> lysozyme, 0.001 % (v/v) protease inhibitor cocktail (Sigma Aldrich) and lysed three  
753 times at 2.5 kBar using a cell disrupter (Constant Systems Limited). Lysate was clarified by

754 two centrifugations during 15 min, 22 000 xg at 4°C then spun for 20 h, 34 700 rpm at 4 °C in  
755 a Type 70 Ti rotor (Beckmann Coulter) through a 37.7 % (w/v) sucrose cushion in Buffer B (20  
756 mM Tris pH 7.4, 10 mM Mg(OAc), 500 mM NH<sub>4</sub>(OAc), 0.5 mM EDTA, 6 mM β-  
757 mercaptoethanol). Sucrose cushions were decanted and ribosome pellets resuspended in  
758 Buffer C (20 mM Tris pH 7.4, 7.5 mM Mg(OAc), 60 mM NH<sub>4</sub>(OAc), 0.5 mM EDTA, 6 mM β-  
759 mercaptoethanol). Finally, 12 mg of ribosomes were loaded onto 10-40 % (w/v) sucrose  
760 gradients in Buffer C and centrifuged 18 h at 20 000 rpm, 4 °C in SW28 rotor (Beckman  
761 Coulter). Gradients were fractionated using Biocomp Piston Gradient Fractionator (BioComp  
762 Instruments), absorbance being measured at 254 nm. Fractions containing 70S ribosomes  
763 were pooled, washed and concentrated in Amicon 50k (Merckmillipore) using Buffer C.  
764 Ribosomes concentration was adjusted to 18-20 μM, then aliquoted and flash frozen in liquid  
765 nitrogen.

766

### 767 **RNA extraction and northern blotting**

768 Total RNA extraction was realized using the RNAsnap method as previously described<sup>85</sup>. In  
769 brief, a preculture of *E. coli* DB10 containing pMMB-*msrDL-msrD*<sub>(1-3)</sub>:*yfp* was grown overnight  
770 at 37 °C under vigorous shaking in LB supplemented with 100 μg.ml<sup>-1</sup> ampicillin. Growth  
771 medium (MH, 100 μg.ml<sup>-1</sup> ampicillin) was inoculated at OD<sub>600</sub>=0.05, and cells were grown at  
772 37 °C and 180 rpm. When OD<sub>600</sub>=0.5, cells were treated (or not) with 1 mM IPTG during 10  
773 min, then treated (or not) with 100 nM erythromycin. Samples of 2 ml were collected (T<sub>0</sub> =  
774 before IPTG was added, T<sub>10</sub>= 10 min after IPTG was added, and 5 min, 15 min, 30 min, 60  
775 min and 120 min after erythromycin was added), then spun during 1 min at 15 000 rpm. Growth  
776 media was removed and cells were resuspended in 100 μl RNAsnap buffer (95 % (v/v)  
777 formamide, 18 mM EDTA, 0.025 % (v/v) SDS, 1 % (v/v) β-mercaptoethanol). Samples were  
778 heated for 10 min at 95 °C then clarified by centrifuging 10 min, at 16 000 rpm at 16 °C. For  
779 northern blotting analysis, 6 μg of total RNAs were resolved on a 1 % (w/v) agarose gel then  
780 transferred onto Amersham Hybond-N+ Membrane (GE Healthcare) by capillary transfer.  
781 Radioactive probe was prepared using 40 pmol of primer 59 and 5'-labelled with 10 U of T4  
782 Polynucleotide Kinase (New England Biolabs) and [<sup>32</sup>P]ATP (150 μCi). Probe was hybridized  
783 overnight at 42 °C using ULTRAhyb-Oligo hybridization buffer (Thermo Fisher Scientific).  
784 Membrane was washed three times at 42 °C during 15 min (once in 2x SSC + 0.1 % (v/v) SDS,  
785 once in 1x SSC + 0.1 % (v/v) SDS and finally in 0.1x SSC + 0.1 % (v/v) SDS). Radioactive  
786 signal was visualized by exposing 4 h a Storage Phosphor Screen BAS-IP MS 2040 (Fujifilm)  
787 then imaged with a Typhoon FLA 9500 (GE Healthcare).

788

## 789 ***In vitro* transcription**

790 *In vitro* transcription was carried out in T7 RiboMAX Large Scale RNA Production System kit  
791 (Promega) according to manufacturer instructions. Briefly, to generate DNA matrix  
792 (Supplementary Table 5), T7 promoter (5'-GCGAATTAATACGACTCACTATAGGG-3') was  
793 added by PCR using primers pair 56/57 (Supplementary Table 4) and pMMB plasmids as  
794 templates. Transcription reactions were incubated 4 h at 37 °C and transcripts were purified  
795 with TRIzol Reagent (Thermo Fisher Scientific) and Direct-zol RNA Miniprep kit (Zymo  
796 Research), samples being eluted in THE Ambion RNA Storage Solution (Thermo Fisher  
797 Scientific). Final concentration was adjusted to 5 pmol.µl<sup>-1</sup>.

798

## 799 **Toeprinting assay**

800 Position of stalled ribosomes on mRNA was determined by toeprinting assay, slightly adapted  
801 from previously described methods<sup>15,86</sup>. *In vitro* translation reactions were performed using  
802 PURExpress ΔRF123 kit and PURExpress ΔRibosome (New England Biolabs) according to  
803 manufacturer instructions. Briefly, prior to *in vitro* translation reactions, 0.5 µl of 500 µM ligand  
804 (e.g. erythromycin etc) was dried in a micro-centrifuge tube, using a SpeedVac vacuum  
805 concentrator (Thermo Fisher Scientific), final concentration being 50 µM once resuspended in  
806 a 5 µl reaction. Reactions were incubated during 15 min at 37 °C using 5 pmol of RNA  
807 templates (generated as described above) and 3.3 µM of purified *E. coli* DB10 ribosomes.  
808 When needed, samples were treated with 100 µM final puromycin and incubated 3 min more.  
809 Immediately, 2 pmol of CY5-labelled primer 58 complementary to NV1 sequence<sup>20</sup> was added  
810 and incubated for 5 min at 37 °C. For each reaction, reverse transcription was performed with  
811 0.5 µl (corresponding to 5 U) of Avian Myeloblastosis Virus Reverse Transcriptase (Promega),  
812 0.1 µl dNTP mix (10 mM), 0.4 µl Pure System Buffer (5 mM K-phosphate pH 7.3, 9 mM  
813 Mg(OAc), 95 mM K-glutamate, 5 mM NH<sub>4</sub>Cl, 0.5 mM CaCl<sub>2</sub>, 1 mM spermidine, 8 mM  
814 putrescine, 1 mM DTT) and incubated 20 min at 37 °C. Reactions were quenched with 1 µl  
815 NaOH 5 M and incubated 15 min at 37 °C. Alkali were therefore neutralized by adding 0.7 µl  
816 HCl 25% immediately supplemented with 20 µl toe-printing resuspension buffer (300 mM  
817 Na(OAc) pH 5.5, 5 mM EDTA, 0.5% (v/v) SDS). Finally, cDNAs were purified using QIAquick  
818 Nucleotide Removal kit (Qiagen), vacuum dried and resuspended in 6 µl formamide dye (95%  
819 (v/v) formamide, 20 mM EDTA, 0.25% (w/v) bromophenol blue). Sanger sequencing was  
820 performed on DNA matrix used for *in vitro* transcription. Briefly, each 20 µl reaction contained  
821 7.5 nM DNA matrix, 75 nM CY5-labelled primer 58, 40 µM of each dNTPs, 0.025 U Taq Pol  
822 (New England Biolabs), 1x Thermo Pol Buffer (New England Biolabs) and corresponding  
823 ddNTPs (625 µM ddCTP/ddTTP/ddATP or 50 µM ddGTP). After PCR, 20 µl formamide dye  
824 was added to each sequencing reaction. Samples were denatured 3 min at 80 °C, then 5 µl of

825 sequencing reaction and 1.5  $\mu$ l of toe-printing reaction were loaded on a 6% acrylamide/bis-  
826 acrylamide (19:1) sequencing gel containing 8 M urea. Gel was resolved by migrating 90 min  
827 at 50 W, then imaged using a Typhoon FLA 9500 (GE Healthcare Life Sciences) using CY5  
828 mode, LPR Ch.2 filter and 635 nm laser.

829

### 830 **Preparation of MsrDL-SRC**

831 A DNA matrix (Supplementary Table 5) was prepared with CloneAmp HiFi PCR Premix  
832 (Takara) using primer pair 56/60 (Supplementary Table 4) and plasmid pMMB-*msrDL*-  
833 *msrD*<sub>(1-3)</sub>:*yfp* as matrix. The corresponding mRNA was generated as described above. The  
834 complete sequence of MsrDL-SRC mRNA is:

835 5'- GGAGCGGAUAACAAGAUACUGAGCACAACAAUAUUGGAGGAAUAAUUUAUGUAAU  
836 CUUAAUUUUCAUGUAACUCUUCUGCUAAAAUCGCAGGGUUUCCUGC -3' (RBS, bold;  
837 *msrDL*, shaded grey; the ATG codon in the P site of stalled ribosomes is underlined). Prior to  
838 *in vitro* translation reaction, 1  $\mu$ l of 500  $\mu$ M erythromycin (50  $\mu$ M final concentration once  
839 resuspended in 10  $\mu$ l) has been dried in a micro-centrifuge tube, using a SpeedVac vacuum  
840 concentrator (Thermo Fisher Scientific). Dried erythromycin has been resuspended in a 10  $\mu$ l  
841 *in vitro* translation reaction carried out in PUREflex 2.0 kit (Genescript), containing 1.83  $\mu$ M  
842 of purified *E. coli* DB10 ribosomes and 3.6  $\mu$ M mRNA (molar ratio 1:2). The reaction has been  
843 incubated for 10 minutes at 37 °C, before adding 100  $\mu$ M final puromycin, and incubated 3 min  
844 more. Reaction was therefore diluted in ribosome purification Buffer C (20 mM Tris pH 7.4, 7.5  
845 mM Mg(OAc), 60 mM NH<sub>4</sub>(OAc), 0.5 mM EDTA, 6 mM  $\beta$ -mercaptoethanol) to reach a  
846 concentration of 150 nM ribosomes. Cryo-EM grids were immediately prepared.

847

### 848 **Cryo-EM grids preparation**

849 Safematic ccu-010 HV carbon coater was used to coat Quantifoil carbon grids (QF-R2/2-Cu)  
850 with a thin carbon layer of approximate thickness of 2nm. Grids were therefore glow discharged  
851 for 30 sec at 2 mA. Then, 4  $\mu$ l of *in vitro* translation reaction diluted to 150 nM were applied,  
852 and after a 2 sec blotting (force 5) and 30 sec waiting time, grids were vitrified in liquid ethane  
853 using a Vitrobot Mark IV (FEI) set to 4 °C and 100 % humidity.

854

### 855 **Image acquisition and processing**

856 Data collection was performed on a Talos Arctica instrument (FEI Company) at 200 kV using  
857 the EPU software (Thermo Fisher Company) for automated data acquisition. Data were  
858 collected at a nominal defocus of -0.5 to -2.7  $\mu$ m at a magnification of 120,000 X yielding a  
859 calibrated pixel size of 1.2 Å. Micrographs were recorded as movie stack on a K2 Summit  
860 direct electron detector (Gatan), each movie stack were fractionated into 65 frames for a total

861 exposure of 6.5 sec corresponding to an electron dose of  $64 \text{ e}^-/\text{\AA}^2$ . MotionCor2<sup>87</sup> was used for  
862 dose weighting, drift and whole-frame motion correction. A dose weighted average image of  
863 the whole stack was used to determine the contrast transfer function with the software Gctf<sup>88</sup>.  
864 Particles were picked using a Laplacian of gaussian function (min diameter 260 Å, max  
865 diameter 320 Å). A total of ~254k particles were extracted from a subset of motion-corrected  
866 images (1523 micrographs) presenting a resolution equal or better than 4 Å with a box size of  
867 360 pixels. The particles were binned three folds for 2D and subsequent 3D classification. After  
868 2 rounds of 2D classification in RELION 3<sup>89</sup>, ~158k particles were selected and submitted to  
869 Relion 3D classification<sup>89</sup>. A class of non-rotated 70S depicting high-resolution features and  
870 bearing a tRNA with various occupancies was selected, representing ~104k particles. This  
871 class was further 3D-classified with a spherical mask engulfing the tRNAs binding sites  
872 (Supplementary Fig. 4b) into 4 classes, thus yielding to P- and E-tRNAs, P-tRNAs only, A- and  
873 P-tRNAs and E-tRNAs 70S reconstructions. Only P- and E-tRNAs and P-tRNAs only  
874 reconstructions were used for further processing, which represents ~62k particles displaying  
875 the same global conformation of the 70S. These particles were re-extracted at the full pixel  
876 size (1.2 Å) and refined through the 3D auto-refinement performed in RELION 3<sup>89</sup> resulting in  
877 a 3 Å reconstruction (Supplementary Fig. 4c), after CTF-refinement, Bayesian particle  
878 polishing and post-processing in RELION 3. In spite of the sufficient local resolution at the  
879 vicinity of MsrDL peptide at the PTC (~3Å), residual movements of the 30S around the 50S  
880 can be deduced by the lower local resolutions of the head and the body of the 30S. In order to  
881 improve their resolution so to derive a complete atomic model of the entire 70S complex, we  
882 applied RELION 3 multi-body refinement by defining three bodies; 50S, 30S-head and 30S-  
883 body. After completion of the refinement, the reconstructions of the 30S-head, 30S-body and  
884 50S reached average resolutions of 3.3, 3.08 and 2.97 Å, respectively. The local resolution  
885 (Supplementary Fig. 4b and 4d) was estimated using ResMap<sup>90</sup>.

886

### 887 **Model building and refinement**

888 The atomic model of erythromycin-stalled *Escherichia coli* 70S ribosome with streptococcal  
889 MsrDL nascent chain was built into cryo-EM maps using Coot and Phenix<sup>91,92</sup>. Insofar as *E.*  
890 *coli* DB10 hasn't been sequenced yet, we assumed that ribosomal proteins and rRNAs were  
891 strictly identical to *E. coli* K12. Furthermore, we did not notice any significant features in the  
892 map. Structure of SpeFL-SRC in response to L-ornithine was used as initial model (PDB  
893 6TC3)<sup>15</sup> and has been fitted in 70S ribosome map EMD-13805. Then, each part of the  
894 ribosome (50S, 30S Body and 30S Head) has been individually inspected in the corresponding  
895 map (respectively EMD-13806, EMD-13807 and EMD-13808) modified if necessary in Coot.  
896 P-site elongator tRNA<sub>Met</sub>tRNA<sup>Met</sup> was modeled *de novo* based on *E. coli* K12 MG1655 *metT*  
897 gene, posttranscriptional modifications were added consistently with Modomics database<sup>93</sup>



898 (<http://genesilico.pl/modomics/>). E-site tRNA<sub>Phe</sub>tRNA<sup>Phe</sup> was derived from crystal structure of  
899 phenylalanine tRNA from *E. coli* (PDB 6Y3G) with minor adjustments<sup>94</sup>. ERY, MsrDL leader  
900 peptide and mRNA were modeled *de novo* in Coot. Final model was refined in map EMD-  
901 13805 using Phenix<sup>92</sup>.

902

### 903 **Figure preparation**

904 Growth curves, histograms and polyribosomes profiles were generated using GraphPad Prism  
905 7 (GraphPad). Sequence alignments were visualized with JalView<sup>95</sup>. Western blotting, northern  
906 blotting and toe-printing gels were analyzed using Fiji<sup>96</sup>. Figures depicting molecular structures  
907 or electronic density maps were prepared using PyMOL Molecular Graphics System, Chimera  
908 and ChimeraX<sup>97,98</sup>.

909

### 910 **Quantification and statistical analysis**

911 Statistical details can be found in the figure legends. Statistical significance was assessed  
912 using unpaired t-Test function in Prism 7 (GraphPad).

913

### 914 **Data and software availability**

915 Cryo-EM map of erythromycin-stalled *Escherichia coli* 70S ribosome with streptococcal MsrDL  
916 nascent chain has been deposited at the Electron Microscopy Data Bank (EMDB) with  
917 accession code EMD-13805, as well as 50S, 30S Body and 30S Head maps obtained after  
918 multibody refinement with accession code EMD-13806, EMD-13807, EMD-13808 respectively.  
919 Corresponding atomic model has been deposited in the Protein Data Bank (PDB) with  
920 accession code 7Q4K.

921

922 **REFERENCES**

- 923 1. Crowe-McAuliffe, C. *et al.* Structural basis for antibiotic resistance mediated by the  
924 *Bacillus subtilis* ABCF ATPase VmlR. *PNAS* **115**, 8978–8983 (2018).
- 925 2. Crowe-McAuliffe, C. *et al.* Structural basis of ABCF-mediated resistance to  
926 pleuromutilin, lincosamide, and streptogramin A antibiotics in Gram-positive  
927 pathogens. *Nat Commun* **12**, 3577 (2021).
- 928 3. Crowe-McAuliffe, C. *et al.* Structural basis for PoxA-mediated resistance to  
929 phenicol and oxazolidinone antibiotics. *Nat Commun* **13**, 1860 (2022).
- 930 4. Lenart, J., Vimberg, V., Vesela, L., Janata, J. & Balikova Novotna, G. Detailed  
931 Mutational Analysis of Vga(A) Interdomain Linker: Implication for Antibiotic  
932 Resistance Specificity and Mechanism. *Antimicrob Agents Chemother* **59**, 1360–  
933 1364 (2015).
- 934 5. Mohamad, M. *et al.* Sal-type ABC-F proteins: intrinsic and common mediators of  
935 pleuromutilin resistance by target protection in staphylococci. *Nucleic Acids*  
936 *Research* **50**, 2128–2142 (2022).
- 937 6. Sharkey, L. K. R., Edwards, T. A. & O’Neill, A. J. ABC-F Proteins Mediate Antibiotic  
938 Resistance through Ribosomal Protection. *mBio* **7**, (2016).
- 939 7. Su, W. *et al.* Ribosome protection by antibiotic resistance ATP-binding cassette  
940 protein. *PNAS* **115**, 5157–5162 (2018).
- 941 8. Boël, G. *et al.* The ABC-F protein EttA gates ribosome entry into the translation  
942 elongation cycle. *Nat Struct Mol Biol* **21**, 143–151 (2014).
- 943 9. Chen, B. *et al.* EttA regulates translation by binding the ribosomal E site and  
944 restricting ribosome-tRNA dynamics. *Nat Struct Mol Biol* **21**, 152–159 (2014).
- 945 10. Fostier, C. R. *et al.* ABC-F translation factors: from antibiotic resistance to immune  
946 response. *FEBS Letters* **595**, 675–706 (2021).
- 947 11. Ousalem, F., Singh, S., Chesneau, O., Hunt, J. F. & Boël, G. ABC-F proteins in  
948 mRNA translation and antibiotic resistance. *Research in Microbiology* **170**, 435–  
949 447 (2019).
- 950 12. Arenz, S. *et al.* Drug Sensing by the Ribosome Induces Translational Arrest via  
951 Active Site Perturbation. *Molecular Cell* **56**, 446–452 (2014).
- 952 13. Arenz, S. *et al.* A combined cryo-EM and molecular dynamics approach reveals  
953 the mechanism of ErmBL-mediated translation arrest. *Nat Commun* **7**, (2016).
- 954 14. Beckert, B. *et al.* Structural and mechanistic basis for translation inhibition by  
955 macrolide and ketolide antibiotics. *Nat Commun* **12**, 4466 (2021).
- 956 15. Herrero del Valle, A. *et al.* Ornithine capture by a translating ribosome controls  
957 bacterial polyamine synthesis. *Nature Microbiology* **5**, 554–561 (2020).
- 958 16. van der Stel, A.-X. *et al.* Structural basis for the tryptophan sensitivity of TnaC-  
959 mediated ribosome stalling. *Nat Commun* **12**, 5340 (2021).
- 960 17. Horinouchi, S. & Weisblum, B. Posttranscriptional modification of mRNA  
961 conformation: Mechanism that regulates erythromycin-induced resistance. *PNAS*  
962 **77**, 7079–7083 (1980).
- 963 18. Ito, K. & Chiba, S. Arrest Peptides: Cis-Acting Modulators of Translation. *Annu.*  
964 *Rev. Biochem.* **82**, 171–202 (2013).
- 965 19. Narayanan, C. S. & Dubnau, D. Evidence for the translational attenuation model:  
966 ribosome-binding studies and structural analysis with an in vitro run-off transcript  
967 of *ermC*. *Nucleic Acids Res* **13**, 7307–7326 (1985).
- 968 20. Vazquez-Laslop, N., Thum, C. & Mankin, A. S. Molecular Mechanism of Drug-  
969 Dependent Ribosome Stalling. *Molecular Cell* **30**, 190–202 (2008).

- 970 21. Gay, K. & Stephens, D. S. Structure and Dissemination of a Chromosomal Insertion  
971 Element Encoding Macrolide Efflux in *Streptococcus pneumoniae*. *The Journal of*  
972 *Infectious Diseases* **184**, 56–65 (2001).
- 973 22. Roberts, M. C. *et al.* Nomenclature for Macrolide and Macrolide-Lincosamide-  
974 Streptogramin B Resistance Determinants. *Antimicrob Agents Chemother* **43**,  
975 2823–2830 (1999).
- 976 23. Daly, M. M., Doktor, S., Flamm, R. & Shortridge, D. Characterization and  
977 Prevalence of MefA, MefE, and the Associated msr(D) Gene in *Streptococcus*  
978 *pneumoniae* Clinical Isolates. *J Clin Microbiol* **42**, 3570–3574 (2004).
- 979 24. Nunez-Samudio, V. & Chesneau, O. Functional interplay between the ATP binding  
980 cassette Msr(D) protein and the membrane facilitator superfamily Mef(E)  
981 transporter for macrolide resistance in *Escherichia coli*. *Research in Microbiology*  
982 **164**, 226–235 (2013).
- 983 25. Tatsuno, I. *et al.* Functional Predominance of msr(D), Which Is More Effective as  
984 mef(A)-Associated Than mef(E)-Associated, Over mef(A)/mef(E) in Macrolide  
985 Resistance in *Streptococcus pyogenes*. *Microbial Drug Resistance* **24**, 1089–1097  
986 (2018).
- 987 26. Zhang, Y. *et al.* Predominant role of msr(D) over mef(A) in macrolide resistance in  
988 *Streptococcus pyogenes*. *Microbiology (Reading)* **162**, 46–52 (2016).
- 989 27. Del Grosso, M., Camilli, R., Iannelli, F., Pozzi, G. & Pantosti, A. The mef(E)-  
990 Carrying Genetic Element (mega) of *Streptococcus pneumoniae*: Insertion Sites  
991 and Association with Other Genetic Elements. *Antimicrob Agents Chemother* **50**,  
992 3361–3366 (2006).
- 993 28. Del Grosso, M., Scotto d’Abusco, A., Iannelli, F., Pozzi, G. & Pantosti, A. Tn2009,  
994 a Tn916-Like Element Containing mef(E) in *Streptococcus pneumoniae*.  
995 *Antimicrob Agents Chemother* **48**, 2037–2042 (2004).
- 996 29. Chancey, S. T. *et al.* Composite mobile genetic elements disseminating macrolide  
997 resistance in *Streptococcus pneumoniae*. *Front. Microbiol.* **6**, (2015).
- 998 30. Iannelli, F. *et al.* Nucleotide sequence of conjugative prophage  $\Phi$ 1207.3 (formerly  
999 Tn1207.3) carrying the mef(A)/msr(D) genes for efflux resistance to macrolides in  
1000 *Streptococcus pyogenes*. *Front Microbiol* **5**, (2014).
- 1001 31. González-Zorn, B. *et al.* Genetic basis for dissemination of armA. *Journal of*  
1002 *Antimicrobial Chemotherapy* **56**, 583–585 (2005).
- 1003 32. Ambrose, K. D., Nisbet, R. & Stephens, D. S. Macrolide Efflux in *Streptococcus*  
1004 *pneumoniae* Is Mediated by a Dual Efflux Pump (mel and mef) and Is Erythromycin  
1005 Inducible. *Antimicrob Agents Chemother* **49**, 4203–4209 (2005).
- 1006 33. Chancey, S. T. *et al.* Transcriptional Attenuation Controls Macrolide Inducible  
1007 Efflux and Resistance in *Streptococcus pneumoniae* and in Other Gram-Positive  
1008 Bacteria Containing mef/mel(msr(D)) Elements. *PLOS ONE* **10**, e0116254 (2015).
- 1009 34. Ramu, H., Mankin, A. & Vazquez-Laslop, N. Programmed drug-dependent  
1010 ribosome stalling. *Mol Microbiol* **71**, 811–824 (2009).
- 1011 35. Sothiselvam, S. *et al.* Macrolide antibiotics allosterically predispose the ribosome  
1012 for translation arrest. *Proc Natl Acad Sci U S A* **111**, 9804–9809 (2014).
- 1013 36. de Block, T. *et al.* WGS of Commensal *Neisseria* Reveals Acquisition of a New  
1014 Ribosomal Protection Protein (MsrD) as a Possible Explanation for High Level  
1015 Azithromycin Resistance in Belgium. *Pathogens* **10**, 384 (2021).
- 1016 37. Lu, C. *et al.* Phenotypic and Genetic Characteristics of Macrolide and Lincosamide  
1017 Resistant *Ureaplasma urealyticum* Isolated in Guangzhou, China. *Curr Microbiol*  
1018 **61**, 44–49 (2010).

- 1019 38. Sharma, P. *et al.* Comparison of Antimicrobial Resistance and Pan-Genome of  
1020 Clinical and Non-Clinical Enterococcus cecorum from Poultry Using Whole-  
1021 Genome Sequencing. *Foods* **9**, 686 (2020).
- 1022 39. Nikaido, H. Multidrug Resistance in Bacteria. *Annual Review of Biochemistry* **78**,  
1023 119–146 (2009).
- 1024 40. Nikaido, H. & Pagès, J.-M. Broad-specificity efflux pumps and their role in multidrug  
1025 resistance of Gram-negative bacteria. *FEMS Microbiol Rev* **36**, 340–363 (2012).
- 1026 41. Datta, N., Hedges, R. W., Becker, D. & Davies, J. Plasmid-determined Fusidic Acid  
1027 Resistance in the Enterobacteriaceae. *Microbiology*, **83**, 191–196 (1974).
- 1028 42. Kannan, K. *et al.* The general mode of translation inhibition by macrolide antibiotics.  
1029 *Proc Natl Acad Sci U S A* **111**, 15958–15963 (2014).
- 1030 43. Vázquez-Laslop, N. & Mankin, A. S. How macrolide antibiotics work. *Trends*  
1031 *Biochem Sci* **43**, 668–684 (2018).
- 1032 44. Murina, V. *et al.* ABCF ATPases Involved in Protein Synthesis, Ribosome  
1033 Assembly and Antibiotic Resistance: Structural and Functional Diversification  
1034 across the Tree of Life. *Journal of Molecular Biology* **431**, 3568–3590 (2019).
- 1035 45. Fürste, J. P. *et al.* Molecular cloning of the plasmid RP4 primase region in a multi-  
1036 host-range tacP expression vector. *Gene* **48**, 119–131 (1986).
- 1037 46. Lutz, R. & Bujard, H. Independent and Tight Regulation of Transcriptional Units in  
1038 Escherichia Coli Via the LacR/O, the TetR/O and AraC/I1-I2 Regulatory Elements.  
1039 *Nucleic Acids Res* **25**, 1203–1210 (1997).
- 1040 47. Dubnau, D. Induction of ermC requires translation of the leader peptide. *EMBO J*  
1041 **4**, 533–537 (1985).
- 1042 48. Dersch, P., Khan, M. A., Mühlen, S. & Görke, B. Roles of Regulatory RNAs for  
1043 Antibiotic Resistance in Bacteria and Their Potential Value as Novel Drug Targets.  
1044 *Front. Microbiol.* **8**, (2017).
- 1045 49. Banerjee, S., Chalissery, J., Bandey, I. & Sen, R. Rho-dependent Transcription  
1046 Termination: More Questions than Answers. *J Microbiol* **44**, 11–22 (2006).
- 1047 50. Ray-Soni, A., Bellecourt, M. J. & Landick, R. Mechanisms of Bacterial Transcription  
1048 Termination: All Good Things Must End. *Annual Review of Biochemistry* **85**, 319–  
1049 347 (2016).
- 1050 51. Naville, M., Ghuillot-Gaudeffroy, A., Marchais, A. & Gautheret, D. ARNold: A web  
1051 tool for the prediction of Rho-independent transcription terminators. *RNA Biology*  
1052 **8**, 11–13 (2011).
- 1053 52. Takada, H. *et al.* Expression of Bacillus subtilis ABCF antibiotic resistance factor  
1054 VmlR is regulated by RNA polymerase pausing, transcription attenuation,  
1055 translation attenuation and (p)ppGpp. *Nucleic Acids Res* gkac497 (2022)  
1056 doi:10.1093/nar/gkac497.
- 1057 53. Yakhnin, A. V. *et al.* NusG controls transcription pausing and RNA polymerase  
1058 translocation throughout the Bacillus subtilis genome. *Proc Natl Acad Sci U S A*  
1059 **117**, 21628–21636 (2020).
- 1060 54. Shimizu, Y. *et al.* Cell-free translation reconstituted with purified components. *Nat*  
1061 *Biotechnol* **19**, 751–755 (2001).
- 1062 55. Hartz, D., McPheeters, D. S., Traut, R. & Gold, L. Extension inhibition analysis of  
1063 translation initiation complexes. in *Methods in Enzymology* vol. 164 419–425  
1064 (Academic Press, 1988).
- 1065 56. Meydan, S. *et al.* Retapamulin-Assisted Ribosome Profiling Reveals the Alternative  
1066 Bacterial Proteome. *Molecular Cell* **74**, 481–493.e6 (2019).


- 1067 57. Muto, H., Nakatogawa, H. & Ito, K. Genetically Encoded but Nonpolypeptide Prolyl-  
1068 tRNA Functions in the A Site for SecM-Mediated Ribosomal Stall. *Molecular Cell*  
1069 **22**, 545–552 (2006).
- 1070 58. Seip, B. & Innis, C. A. How Widespread is Metabolite Sensing by Ribosome-  
1071 Arresting Nascent Peptides? *Journal of Molecular Biology* **428**, 2217–2227 (2016).
- 1072 59. Vázquez-Laslop, N. *et al.* Role of antibiotic ligand in nascent peptide-dependent  
1073 ribosome stalling. *Proc. Natl. Acad. Sci. U.S.A.* **108**, 10496–10501 (2011).
- 1074 60. Hansen, J. L. *et al.* The Structures of Four Macrolide Antibiotics Bound to the Large  
1075 Ribosomal Subunit. *Molecular Cell* **10**, 117–128 (2002).
- 1076 61. Mao, J. C. & Robishaw, E. E. Effects of macrolides on peptide-bond formation and  
1077 translocation. *Biochemistry* **10**, 2054–2061 (1971).
- 1078 62. Poulsen, S. M., Kofoed, C. & Vester, B. Inhibition of the ribosomal peptidyl  
1079 transferase reaction by the mycarose moiety of the antibiotics carbomycin,  
1080 spiramycin and tylosin1 1Edited by D. E. Draper. *Journal of Molecular Biology* **304**,  
1081 471–481 (2000).
- 1082 63. Emmanuel, J. S., Sengupta, A., Gordon, E. R., Noble, J. T. & Cruz-Vera, L. R. The  
1083 regulatory TnaC nascent peptide preferentially inhibits release factor 2-mediated  
1084 hydrolysis of peptidyl-tRNA. *J Biol Chem* **294**, 19224–19235 (2019).
- 1085 64. Ohashi, Z. *et al.* Characterization of C+ located in the first position of the anticodon  
1086 of Escherichia coli tRNAMet as N4-acetylcytidine. *Biochimica et Biophysica Acta*  
1087 (*BBA*) - *Nucleic Acids and Protein Synthesis* **262**, 209–213 (1972).
- 1088 65. Varshney, U., Lee, C. P. & RajBhandary, U. L. From elongator tRNA to initiator  
1089 tRNA. *PNAS* **90**, 2305–2309 (1993).
- 1090 66. Pierson, W. E. *et al.* Uniformity of Peptide Release Is Maintained by Methylation of  
1091 Release Factors. *Cell Reports* **17**, 11–18 (2016).
- 1092 67. Schmeing, T. M., Huang, K. S., Strobel, S. A. & Steitz, T. A. An induced-fit  
1093 mechanism to promote peptide bond formation and exclude hydrolysis of peptidyl-  
1094 tRNA. *Nature* **438**, 520–524 (2005).
- 1095 68. Arenz, S. *et al.* Molecular basis for erythromycin-dependent ribosome stalling  
1096 during translation of the ErmBL leader peptide. *Nature Communications* **5**, 3501  
1097 (2014).
- 1098 69. Lovmar, M. *et al.* The Molecular Mechanism of Peptide-mediated Erythromycin  
1099 Resistance \*. *Journal of Biological Chemistry* **281**, 6742–6750 (2006).
- 1100 70. Tenson, T., Xiong, L., Kloss, P. & Mankin, A. S. Erythromycin Resistance Peptides  
1101 Selected from Random Peptide Libraries\*. *Journal of Biological Chemistry* **272**,  
1102 17425–17430 (1997).
- 1103 71. Koch, M., Willi, J., Pradère, U., Hall, J. & Polacek, N. Critical 23S rRNA interactions  
1104 for macrolide-dependent ribosome stalling on the ErmCL nascent peptide chain.  
1105 *Nucleic Acids Res* **45**, 6717–6728 (2017).
- 1106 72. Vázquez-Laslop, N., Ramu, H., Klepacki, D., Kannan, K. & Mankin, A. S. The key  
1107 function of a conserved and modified rRNA residue in the ribosomal response to  
1108 the nascent peptide. *EMBO J* **29**, 3108–3117 (2010).
- 1109 73. Vimberg, V. *et al.* Ribosome-Mediated Attenuation of vga(A) Expression Is Shaped  
1110 by the Antibiotic Resistance Specificity of Vga(A) Protein Variants. *Antimicrobial*  
1111 *Agents and Chemotherapy* **64**, (2020).
- 1112 74. Jacquet, E. *et al.* ATP Hydrolysis and Pristinamycin IIA Inhibition of the  
1113 Staphylococcus aureus Vga(A), a Dual ABC Protein Involved in Streptogramin A  
1114 Resistance \*. *Journal of Biological Chemistry* **283**, 25332–25339 (2008).
- 1115 75. Mayford, M. & Weisblum, B. Conformational alterations in the ermC transcript in  
1116 vivo during induction. *EMBO J* **8**, 4307–4314 (1989).

- 1117 76. Dar, D. *et al.* Term-seq reveals abundant ribo-regulation of antibiotics resistance in  
1118 bacteria. *Science* **352**, aad9822 (2016).
- 1119 77. Koberska, M. *et al.* Beyond Self-Resistance: ABCF ATPase LmrC Is a Signal-  
1120 Transducing Component of an Antibiotic-Driven Signaling Cascade Accelerating  
1121 the Onset of Lincomycin Biosynthesis. *mBio* **12**, e0173121 (2021).
- 1122 78. Ohki, R., Tateno, K., Takizawa, T., Aiso, T. & Murata, M. Transcriptional  
1123 Termination Control of a Novel ABC Transporter Gene Involved in Antibiotic  
1124 Resistance in *Bacillus subtilis*. *J Bacteriol* **187**, 5946–5954 (2005).
- 1125 79. Dunkle, J. A., Xiong, L., Mankin, A. S. & Cate, J. H. D. Structures of the *Escherichia*  
1126 *coli* ribosome with antibiotics bound near the peptidyl transferase center explain  
1127 spectra of drug action. *Proc Natl Acad Sci U S A* **107**, 17152–17157 (2010).
- 1128 80. Desai, N. *et al.* Elongational stalling activates mitoribosome-associated quality  
1129 control. *Science* **370**, 1105–1110 (2020).
- 1130 81. Golubev, A. *et al.* Cryo-EM structure of the ribosome functional complex of the  
1131 human pathogen *Staphylococcus aureus* at 3.2 Å resolution. *FEBS Letters* **594**,  
1132 3551–3567 (2020).
- 1133 82. Li, W. *et al.* Structural basis for selective stalling of human ribosome nascent chain  
1134 complexes by a drug-like molecule. *Nat Struct Mol Biol* **26**, 501–509 (2019).
- 1135 83. Croucher, N. J. *et al.* Rapid pneumococcal evolution in response to clinical  
1136 interventions. *Science* **331**, 430–434 (2011).
- 1137 84. Miller, J. R. *GraphPad Prism Version 4.0 Step-by-Step Examples*. vol. GraphPad  
1138 Software Inc., San Diego (GraphPad Software Inc., San Diego, 2003).
- 1139 85. Stead, M. B. *et al.* RNAsnap<sup>TM</sup>: a rapid, quantitative and inexpensive, method for  
1140 isolating total RNA from bacteria. *Nucleic Acids Res* **40**, e156 (2012).
- 1141 86. Seefeldt, A. C. *et al.* The proline-rich antimicrobial peptide Onc112 inhibits  
1142 translation by blocking and destabilizing the initiation complex. *Nature Structural &*  
1143 *Molecular Biology* **22**, 470–475 (2015).
- 1144 87. Zheng, S. Q. *et al.* MotionCor2 - anisotropic correction of beam-induced motion for  
1145 improved cryo-electron microscopy. *Nat Methods* **14**, 331–332 (2017).
- 1146 88. Zhang, K. Gctf: Real-time CTF determination and correction. *J Struct Biol* **193**, 1–  
1147 12 (2016).
- 1148 89. Zivanov, J. *et al.* New tools for automated high-resolution cryo-EM structure  
1149 determination in RELION-3. *eLife* **7**, e42166 (2018).
- 1150 90. Kucukelbir, A., Sigworth, F. J. & Tagare, H. D. The Local Resolution of Cryo-EM  
1151 Density Maps. *Nat Methods* **11**, 63–65 (2014).
- 1152 91. Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. *Acta*  
1153 *Cryst D* **60**, 2126–2132 (2004).
- 1154 92. Liebschner, D. *et al.* Macromolecular structure determination using X-rays,  
1155 neutrons and electrons: recent developments in Phenix. *Acta Cryst D* **75**, 861–877  
1156 (2019).
- 1157 93. Boccaletto, P. *et al.* MODOMICS: a database of RNA modification pathways. 2017  
1158 update. *Nucleic Acids Res* **46**, D303–D307 (2018).
- 1159 94. Bourgeois, G. *et al.* Structural basis of the interaction between cyclodipeptide  
1160 synthases and aminoacylated tRNA substrates. *RNA* **26**, 1589–1602 (2020).
- 1161 95. Waterhouse, A. M., Procter, J. B., Martin, D. M. A., Clamp, M. & Barton, G. J.  
1162 Jalview Version 2—a multiple sequence alignment editor and analysis workbench.  
1163 *Bioinformatics* **25**, 1189–1191 (2009).
- 1164 96. Schindelin, J. *et al.* Fiji: an open-source platform for biological-image analysis.  
1165 *Nature Methods* **9**, 676–682 (2012).

- 1166 97. Goddard, T. D. *et al.* UCSF ChimeraX: Meeting modern challenges in visualization  
1167 and analysis. *Protein Sci* **27**, 14–25 (2018).  
1168 98. Pettersen, E. F. *et al.* UCSF Chimera—A visualization system for exploratory  
1169 research and analysis. *Journal of Computational Chemistry* **25**, 1605–1612 (2004).  
1170

1171


**FIGURE 1**






1172

**FIGURE 2**




1173

FIGURE 3




1174

FIGURE 4



1175

**FIGURE 5**



1176

**FIGURE 6**

